Professor Val Gebski

Professor of Biostatistics and Research Methodology
Medicine, Sydney Medical School
NHMRC Clinical Trials Centre

Telephone +61 2 9562 5000
Fax +61 2 9565 1863

Map

Biographical details

Professor Val Gebski is head of biostatistics and research methodology at the NHMRC Clinical Trials Centre which he joined in 1988. He has extensive knowledge of clinical trial methodology, conduct and analysis and is the Group Statistician for a number of national collaborative clinical trials groups in oncology. He has a BA and MStat and is also involved in curriculum development and teaching in the Masters of Public Health, Clinical Epidemiology and Medicine at the University of Sydney. He is the statistical examiner for the Royal Australian and New Zealand College of Radiologists.

Research interests

• Methods for Clinical Trials design

• Competing risks in studies with time-to-event outcomes • Study designs examining the impact of biomarkers • Novel statistical methods for clinical trials analysis

Selected grants

2013

  • Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours: An Australian-Led, International Randomised Trial; Grimison P, Toner G, Stockler M, Friedlander M, Thomson D, Gebski V, King M, Quinn D, Singhal N; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • Adding mitomycin C to intravesical BCG for high-risk, non-muscle-invasive bladder cancer: a randomised phase 3 trial; Hayne D, Patel M, Stockler M, Sengupta S, Frydenberg M, Chalasani V, Gebski V, Davis I; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • A randomised phase III trial of preoperative chemoradiotherapy vs preoperative chemotherapy for resectable gastric cancer; Leong T, Zalcberg J, Smithers B, Boussioutas A, Haustermans K, Gebski V, Wong R, Lordick F, Swallow C, Michael M; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Advancing the evidence base for care and policy in priority health areas; Simes R, Keech A, Gebski V, Stockler M, Caterson I, Colagiuri S, Schofield D, Marschner C; National Health and Medical Research Council (NHMRC)/Program Grants.
  • Development and operational support for ANZGOG through the NHMRC Clinical Trials Centre: A NSW lead initiative.; Brand A, Friedlander M, Stockler M, Sjoquist K, Gebski V; Cancer Institute New South Wales/Cooperative Clinical Trial (CCT) Grants.

2011

  • Reducing Impulsive Behaviour in Repeat Violent Offenders Using a Selective Serotonin Reuptake Inhibitor (Zoloft); Gebski V, Keech A, Chappell D; National Health and Medical Research Council (NHMRC)/Partnership Projects.

2010

  • The concordance of different lymphoscintigraphy techniques used in breast cancer sentinel lymph node mapping; Noushi F, Spillane A, Uren R, Gebski V; National Breast Cancer Foundation/Pilot Study Grants.

2009

  • Biostatistics, quality assurance and data systems for cancer trial groups activities based at the NHMRC Clinical Trials Centre; Gebski V, Simes R, Hague W, Gainford M, Stockler M, Goldstein D, Friedlander M, Grimison P; Cancer Institute New South Wales/Clinical Trials Infrastructure Grants.
  • Randomised phase III study of preop-chemoradiotherapy versus preop-chemotherapy for resectable gastric cancer; Leong T, Zalcberg J, Watson D, Spry N, Gebski V, Smithers B, Watson D, Michael M; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2008

  • Clinical trials advances for better health outcomes; Simes R, Keech A, Gebski V, Stockler M; National Health and Medical Research Council (NHMRC)/Project Grants.

2007

  • Snac 1: A randomised trial on sentinel node based management versus axillary clearance for women with small breast cancers; Gill P, Wetzig N, Gebski V, Ung O, Campbell I, Oliver D; National Health and Medical Research Council (NHMRC)/Project Grants.

2006

  • Nhmrc Clinical Trials Centre Clinical Trials Methodology And Practice Consultancy, Incorporating Utilisation And Enhancement Of A Web-Based Electronic Clinical Trials Data Management System And Repository; Simes R, Keech A, Gebski V, Hague W, Stockler M; National Health and Medical Research Council (NHMRC)/Enabling Grants.
  • TBA: Roche Diagnostics; Hughes C, Gebski V, Keech A, Dignan R; Roche Products Pty Limited/Research Grant.

2005

  • Sentinal node biopsy versus axillary clearence in breast cancer: the SNAC trial; Stockler M, Gebski V, Simes R; National Breast Cancer Foundation/Kathleen Cuningham Research Grant.

2003

  • Advances in clinical trials research and evidence-based decision making; Marschner C, Stockler M, Keech A, Simes R, Gebski V; National Health and Medical Research Council (NHMRC)/Program Grants.

2000

  • Provision of assessment and research related services on medical technologies and procedures for the Medical Services Advisory Committee (MSAC); Simes R, Eckermann S, Keech A, Irwig L, Ghersi D, Stockler M, Gebski V, Eckermann S, Lord S, Howard K, Salkeld G; Department of Health and Ageing (Federal)/Research Support.

Selected publications

Download citations: PDF RTF Endnote

Edited Books

  • Keech, A., Gebski, V., Pike, R. (2007). Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials. Sydney: AMPCo.

Book Chapters

  • Cook, D., Keech, A., Gebski, V., Pike, R., Wonders, S. (2008). Balancing the outcomes: reporting harms (adverse events). In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 132-142). Sydney: AMPCo.
  • Keech, A., Gebski, V., Forder, P. (2007). Allocation concealment and blinding: when ignorance is bliss. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 54-64). Sydney: AMPCo.
  • Gebski, V., Keech, A., Simes, R. (2007). Applying subgroup analysis to individual patient decisions. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 114-122). Sydney: AMPCo.
  • Keech, A., Gebski, V., Burgess, D. (2007). Baseline data in clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 86-91). Sydney: AMPCo.
  • Keech, A., Gebski, V., Kirby, A. (2007). Determining the sample size in a clinical trial. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 28-38). Sydney: AMPCo.
  • Keech, A., Gebski, V., Vachan, B. (2007). Flow of participants in randomised studies. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 72-78). Sydney: AMPCo.
  • Keech, A., Seale, J., Gebski, V. (2007). Generalising the results of trials to clinical practice. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 149-153). Sydney: AMPCo.
  • Keech, A., Gebski, V., Heritier, S. (2007). Inclusion of patients in clinical trial analysis: the intention-to-treat principle. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 92-98). Sydney: AMPCo.
  • Keech, A., Gebski, V., Pike, R., Granger, R. (2007). Interpreting the results of a clinical trial. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 143-148). Sydney: AMPCo.
  • Keech, A., Ghersi, D., Gebski, V., Pike, R. (2007). Introducing the report of a randomised controlled trial: the title, abstract, scientific background and rationale. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 8-10). Sydney: AMPCo.
  • O'Connell, R., Gebski, V., Keech, A. (2007). Making sense of trial results: outcomes and estimation. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 99-104). Sydney: AMPCo.
  • Keech, A., Gebski, V. (2007). Managing the resource demand of a large sample in clinical trials: can you succeed with fewer subjects? In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 39-45). Sydney: AMPCo.
  • Keech, A., Gebski, V., Lord, S. (2007). Multiple analyses in clinical trials: sound science or data dredging? In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 123-131). Sydney: AMPCo.
  • Wilcken, N., Gebski, V., Pike, R., Keech, A. (2007). Putting results of a clinical trial into perspective. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 154-161). Sydney: AMPCo.
  • Beller, E., Gebski, V., Keech, A. (2007). Randomisation in clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 46-53). Sydney: AMPCo.
  • Gebski, V., Beller, E., Keech, A., Van Der Weyden, M. (2007). Randomised Controlled Trials: Elements of a Good Study. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 7-22). Sydney: AMPCo.
  • Keech, A., Gebski, V., Beller, E., Van Der Weyden, M. (2007). Randomised controlled trials: elements of a good study. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 1-7). Sydney: AMPCo.
  • Hague, W., Keech, A., Gebski, V., Pike, R. (2007). Recruitment to randomised studies. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 78-85). Sydney: AMPCo.
  • Keech, A., Gebski, V. (2007). Selecting participants for clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 11-15). Sydney: AMPCo.
  • Brighton, J., Gebski, V., Keech, A. (2007). Specifying intervention in a clinical trial. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 16-20). Sydney: AMPCo.
  • Keech, A., Gebski, V., Marschner, C. (2007). Specifying objectives and outcomes for clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 21-26). Sydney: AMPCo.
  • Keech, A., Gebski, V. (2007). Statistical methods in clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 65-71). Sydney: AMPCo.
  • Cook, D., Keech, A., Gebski, V. (2007). Subgroup analysis in clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 105-113). Sydney: AMPCo.

Journals

  • Grimison, P., Stockler, M., Chatfield, M., Thomson, D., Gebski, V., Friedlander, M., Boland, A., Houghton, B., Gruney, H., Rosenthal, M., et al (2014). Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Annals of Oncology, 25(1), 143-148. [More Information]
  • Tran, B., Armstrong, B., Ebeling, P., English, D., Kimlin, M., van der Pols, J., Venn, A., Gebski, V., Whiteman, D., Webb, P., et al (2014). Effect of vitamin D supplementation on antibiotic use: a randomized controlled trial. The American Journal of Clinical Nutrition, 99(1), 156-161. [More Information]
  • Beumer, J., Gill, G., Campbell, I., Wetzig, N., Ung, O., Farshid, G., Uren, R., Stockler, M., Gebski, V. (2014). Sentinel node biopsy and large (≥3 cm) breast cancer. ANZ Journal of Surgery, 84(3), 117-120. [More Information]
  • Lee, C., Simes, R., Brown, C., Gebski, V., Pfisterer, J., Swart, A., Berton-Rigaud, D., Plante, M., Skeie-Jensen, T., Vergote, I., Lord, S., et al (2013). A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. Annals of Oncology, 24(4), 937-943. [More Information]
  • Tebbutt, N., Parry, M., Zannino, D., Strickland, A., van Hazel, G., Pavlakis, N., Ganju, V., Mellor, D., Dobrovic, A., Gebski, V. (2013). Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. British Journal of Cancer, 108(4), 771-774. [More Information]
  • Najim, M., Cross, S., Gebski, V., Palme, C., Morgan, G., Veness, M. (2013). Early-stage squamous cell carcinoma of the lip: The Australian experience and the benefits of radiotherapy in improving outcome in high-risk patients after resection. Head and Neck, 35(10), 1426-1430. [More Information]
  • Blinman, P., Gainford, C., Donoghoe, M., Martyn, J., Bloomfield, P., Grant, P., Kichenadasse, G., Vaughan, M., Brand, A., Shannon, C., Gebski, V., Stockler, M., et al (2013). Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. Journal of Gynecologic Oncology, 24(4), 359-366. [More Information]
  • Noushi, F., Spillane, A., Uren, R., Cooper, R., Allwright, S., Snook, K., Gillett, D., Pearce, A., Gebski, V. (2013). High discordance rates between sub-areolar and peri-tumoural breast lymphoscintigraphy. European Journal of Surgical Oncology, 39(10), 1053-1060. [More Information]
  • Obermair, A., Janda, M., Gebski, V. (2013). Identification of doctors at risk of recurrent complaints: a national study of healthcare complaints in Australia. BMJ Quality and Safety, 22(10), 878. [More Information]
  • Carus, A., Gurney, H., Gebski, V., Harnett, P., Hui, R., Kefford, R., Wilcken, N., Ladekarl, M., von der Maase, H., Donskov, F. (2013). Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. Journal of Translational Medicine, 11(1), 1-10. [More Information]
  • Lee, C., Brown, C., Gralla, R., Hirsh, V., Thongprasert, S., Tsai, C., Tan, E., Ho, J., Chu, D., Zaatar, A., Gebski, V., et al (2013). Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis. National Cancer Institute. Journal, 105(9), 595-605. [More Information]
  • Wang, J., Palme, C., Wang, A., Morgan, G., Gebski, V., Veness, M. (2013). In patients with metastatic cutaneous head and neck squamous cell carcinoma to cervical lymph nodes, the extent of neck dissection does not influence outcome. The Journal of Laryngology and Otology, 127(Suppl. S1), S2-S7. [More Information]
  • Dignan, R., Keech, A., Gebski, V., Mann, K., Hughes, C. (2013). Is home warfarin self-management effective? Results of the randomised Self-Management of Anticoagulation Research Trial. International Journal of Cardiology, 168(6), 5378-5384. [More Information]
  • Fox, P., Hudson, M., Brown, C., Lord, S., Gebski, V., de Souza, P., Lee, C. (2013). Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. British Journal of Cancer, 109(1), 147-153. [More Information]
  • Tran, B., Armstrong, B., McGeechan, K., Ebeling, P., English, D., Kimlin, M., Lucas, R., van der Pols, J., Venn, A., Gebski, V., et al (2013). Predicting vitamin D deficiency in older Australian adults. Clinical Endocrinology, 79(5), 631-640. [More Information]
  • Hacker, N., Barlow, E., Scurry, J., Gebski, V., Farrell, R., Robertson, G., Friedlander, M., Jackson, M. (2013). Primary surgical management with tailored adjuvant radiation for stage IB2 cervical cancer. Obstetrics and Gynecology, 121(4), 765-772. [More Information]
  • Wang, A., Palme, C., Wang, J., Morgan, G., Gebski, V., GILCHRIST, J., Veness, M. (2013). Quality of life assessment in patients treated for metastatic cutaneous squamous cell carcinoma of the head and neck. The Journal of Laryngology and Otology, 127(Suppl. S2), S39-S47. [More Information]
  • Olver, I., Grimison, P., Chatfield, M., Stockler, M., Toner, G., Gebski, V., Harrup, R., Underhill, C., Kichenadasse, G., Singhal, N., Boland, A., McDonald, A., et al (2013). Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. Supportive Care in Cancer, 21(6), 1561-1568. [More Information]
  • Graves, N., Janda, M., Merollini, K., Gebski, V., Obermair, A. (2013). The cost-effectiveness of total laparoscopic hysterectomy compared to total abdominal hysterectomy for the treatment of early stage endometrial cancer. BMJ Open, 3(4), 1-5. [More Information]
  • Garner, A., Fearnside, M., Gebski, V. (2013). The study protocol for the Head Injury Retrieval Trial (HIRT): a single centre randomised controlled trial of physician prehospital management of severe blunt head injury compared with management by paramedics. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 21, 1-8. [More Information]
  • Lee, C., Gebski, V., Coates, A., Veillard, A., Harvey, V., Tattersall, M., Byrne, M., Brigham, B., Forbes, J., Simes, R. (2013). Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone. SpringerPlus, 2(391), 1-10. [More Information]
  • Small, K., Kelly, C., Beldham-Collins, R., Gebski, V. (2013). Whole breast and excision cavity radiotherapy plan comparison: Conformal radiotherapy with sequential boost versus intensity-modulated radiation therapy with a simultaneously integrated boost. Journal of Medical Radiation Sciences, 60(1), 16-24. [More Information]
  • Venkateswaran, L., Butow, P., Jansen, J., Wilcken, N., WONG, M., Hui, R., Szonyi, G., Gebski, V., Naganathan, V., Horvath, L., Tattersall, M. (2012). Decision making in older patients with advanced cancer: Does doctor know best? Medical Journal of Australia, 196(1), 35-39. [More Information]
  • Weickhardt, A., Price, T., Chong, G., Gebski, V., Pavlakis, N., Johns, T., Azad, A., Skrinos, E., Fluck, K., Dobrovic, A., et al (2012). Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. Journal of Clinical Oncology, 30(13), 1505-1512. [More Information]
  • Sullivan, D., Olsson, A., Scott, R., Kim, J., Xue, A., Gebski, V., Wasserman, S., Stein, E. (2012). Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA: The Journal of the American Medical Association, 308(23), 2497-2506. [More Information]
  • Baker, J., Obermair, A., Gebski, V., Janda, M. (2012). Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: A meta-analysis and systematic review of the literature. Gynecologic Oncology, 125(1), 263-270. [More Information]
  • Coburn, N., Beldham-Collins, R., Westling, J., Trovato, J., Gebski, V. (2012). Evaluation of flexible and rigid (class solution) radiation therapy conformal prostate planning protocols. Medical Dosimetry, 37(1), 5-8. [More Information]
  • Wagner, U., Marth, C., Largillier, R., Kaern, J., Brown, C., Heywood, M., Bonaventura, T., Vergote, I., Piccirillo, M., Fossati, R., et al (2012). Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. British Journal of Cancer, 107(4), 588-591. [More Information]
  • Brundage, M., Gropp, M., Mefti, F., Mann, K., Lund, B., Gebski, V., Wolfram, G., Reed, N., Pignata, S., Ferrero, A., Brown, C., et al (2012). Health-related quality of life in recurrent platinum-sensitive ovarian cancer - results from the CALYPSO trial. Annals of Oncology, 23(8), 2020-2027. [More Information]
  • Obermair, A., Janda, M., Baker, J., Kondalsamy-Chennakesavan, S., Brand, A., Hogg, R., Jobling, T., Land, R., Manolitsas, T., Nascimento, M., Gebski, V., et al (2012). Improved surgical safety after laparoscopic compared to open surgery for apparent early stage endometrial cancer: Results from a randomised controlled trial. European Journal of Cancer, 48(8), 1147-1153. [More Information]
  • Lord, S., Marinovich, M., Patterson, J., Wilcken, N., Kiely, B., Gebski, V., Crossing, S., Roder, D., Gattellari, M., Houssami, N. (2012). Incidence of metastatic breast cancer in an Australian population-based cohort of women with non-metastatic breast cancer at diagnosis. Medical Journal of Australia, 196(11), 688-692. [More Information]
  • Howle, J., Hughes, T., Gebski, V., Veness, M. (2012). Merkel cell carcinoma: An Australian perspective and the importance of addressing the regional lymph nodes in clinically node-negative patients. Journal Of The American Academy Of Dermatology, 67(1), 33-40. [More Information]
  • Gebski, V., Ellingson, K., Edwards, J., Jernigan, J., Kleinbaum, D. (2012). Modelling interrupted time series to evaluate prevention and control of infection in healthcare. Epidemiology and Infection, 140(12), 2131-2141. [More Information]
  • Kifley, A., Heller, G., Beath, K., Bulger, D., Ma, J., Gebski, V. (2012). Multilevel latent variable models for global health-related quality of life assessment. Statistics in Medicine, 31(11-12), 1249-1264. [More Information]
  • Wang, J., Palme, C., Morgan, G., Gebski, V., Wang, A., Veness, M. (2012). Predictors of outcome in patients with metastatic cutaneous head and neck squamous cell carcinoma involving cervical lymph nodes: Improved survival with the addition of adjuvant radiotherapy. Head and Neck, 34(11), 1524-1528. [More Information]
  • Tran, B., Armstrong, B., Carlin, J., Ebeling, P., English, D., Kimlin, M., Rahman, B., van der Pols, J., Venn, A., Gebski, V., et al (2012). Recruitment and Results of a Pilot Trial of Vitamin D Supplementation in the General Population of Australia. Journal of Clinical Endocrinology and Metabolism, 97(12), 4473-4480. [More Information]
  • Kondalsamy-Chennakesavan, S., Janda, M., Gebski, V., Baker, J., Brand, A., Hogg, R., Jobling, T., Land, R., Manolitsas, T., Nascimento, M., et al (2012). Risk factors to predict the incidence of surgical adverse events following open or laparoscopic surgery for apparent early stage endometrial cancer: Results from a randomised controlled trial. European Journal of Cancer, 48(14), 2155-2162. [More Information]
  • Goldstein, D., Spry, N., Cummins, M., Brown, C., van Hazel, G., Carroll, S., Selva-Nayagam, S., Borg, M., Ackland, S., Wratten, C., Hruby, G., Horvath, L., Gebski, V., et al (2012). The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. British Journal of Cancer, 106(1), 61-69. [More Information]
  • Nicklin, J., Janda, M., Gebski, V., Jobling, T., Land, R., Manolitsas, T., McCartney, A., Nascimento, M., Perrin, L., Baker, J., et al (2012). The utility of serum CA-125 in predicting extra-uterine disease in apparent early stage endometrial cancer. International Journal of Cancer, 131(4), 885-890. [More Information]
  • Lee, C., Hudson, M., Stockler, M., Coates, A., Ackland, S., Gebski, V., Lord, S., Friedlander, M., Boyle, F., Simes, R. (2011). A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. Breast Cancer Research and Treatment, 129(2), 467-476. [More Information]
  • Stockler, M., Harvey, V., Francis, P., Byrne, M., Ackland, S., Fitzharris, B., Van Hazel, G., Wilcken, N., Grimison, P., Nowak, A., Zannino, D., Gebski, V., Coates, A., et al (2011). Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. Journal of Clinical Oncology, 29(34), 4498-4504. [More Information]
  • Lee, C., Gurney, H., Brown, C., Sorio, R., Donadello, N., Tulunay, G., Meier, W., Bacon, M., Maenpaa, J., Petru, E., Gebski, V., Lord, S., Simes, R., et al (2011). Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. British Journal of Cancer, 105(3), 360-365. [More Information]
  • Lee, C., Friedlander, M., Brown, C., Gebski, V., Georgoulopoulos, A., Vergote, I., Pignata, S., Donadello, N., Schmalfeldt, B., Delva, R., Lord, S., Simes, R., et al (2011). Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer. National Cancer Institute. Journal, 103(17), 1338-1342. [More Information]
  • Davis, T., Ting, R., Best, J., Donoghoe, M., Drury, P., Sullivan, D., Jenkins, A., O'Connell, R., Whiting, M., Glasziou, P., Simes, R., Gebski, V., Keech, A., et al (2011). Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia: clinical and experimental diabetes and metabolism, 54(2), 280-290.
  • Brown, A., Gebski, V., Beldham-Collins, R., Hardcastle-Fowler, T., Do, V., Turner, S. (2011). Gold seed fiducial markers for prostate radiation therapy: describing prostate motion. The Radiographer, 58(3), 28-31.
  • Noushi, F., Spillane, A., Uren, R., Gebski, V. (2011). Internal Mammary Lymph Node Metastasis in Breast Cancer: Predictive Models to Assist with Prognostic Influence. The Breast, 20(3), 278-283. [More Information]
  • Lee, C., Simes, R., Brown, C., Lord, S., Wagner, U., Plante, M., Vergote, I., Pisano, C., Parma, G., Burges, A., Gebski, V., et al (2011). Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. British Journal of Cancer, 105(8), 1144-1150. [More Information]
  • Luckett, T., Goldstein, D., Butow, P., Gebski, V., Aldridge, L., McGrane, J., Ng, W., King, M. (2011). Psychological morbidity and quality of life of ethnic minority patients with cancer: a systematic review and meta-analysis. The Lancet Oncology, 12(13), 1240-1248. [More Information]
  • Oh, B., Hu, G., Kao, S., Gebski, V., Walls, R., Truong, L., Beale, P., Clarke, S. (2011). Safety and tolerability of Chinese Herbal Medicine with cancer patients receiving chemotherapy. WebmedCentral, 2(Article ID: WMC001671), 1-11.
  • Clarke, S., Yip, S., Brown, C., van Hazel, G., Ransom, D., Goldstein, D., Jeffrey, G., Tebbutt, N., Buck, M., Lowenthal, R., Boland, A., Gebski, V., Simes, R., et al (2011). Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. European Journal of Cancer, 47(12), 1826-1836. [More Information]
  • Sjoquist, K., Burmeister, B., Smithers, B., Zalcberg, J., Simes, R., Barbour, A., Gebski, V. (2011). Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. The Lancet Oncology, 12(7), 681-692. [More Information]
  • Ellingson, K., Muder, R., Jain, R., Kleinbaum, D., Feng, P., Cunningham, C., Squier, C., Lloyd, J., Edwards, J., Gebski, V., et al (2011). Sustained Reduction in the Clinical Incidence of Methicillin-Resistant Staphylococcus Aureus Colonization or Infection Associated with a Multifaceted Infection Control Intervention. Infection Control and Hospital Epidemiology, 32(1), 1-8. [More Information]
  • Changsirivathanathamrong, D., Wang, Y., Rajbhandari, D., Maghzal, G., Mak, W., Woolfe, C., Duflou, J., Gebski, V., Dos Remedios, C., Celermajer, D., Stocker, R. (2011). Tryptophan metabolism to kynurenine is a potential novel contributor to hypotension in human sepsis. Critical Care Medicine, 39(12), 2678-2683. [More Information]
  • Tebbutt, N., Wilson, K., Gebski, V., Cummins, M., Zannino, D., van Hazel, G., Robinson, B., Broad, A., Ganju, V., Ackland, S., Stockler, M., Simes, R., et al (2010). Capecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study. Journal of Clinical Oncology, 28(19), 3191-3198. [More Information]
  • Grimison, P., Stockler, M., Thomson, D., Olver, I., Harvey, V., Gebski, V., Lewis, C., Levi, J., Boyer, M., Gurney, H., Boland, A., Simes, R., et al (2010). Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial. National Cancer Institute. Journal, 102(16), 1253-1262. [More Information]
  • Davis, T., Ting, R., Best, J., Donoghoe, M., Drury, P., Sullivan, D., Jenkins, A., O'Connell, R., Whiting, M., Glasziou, P., Simes, R., Gebski, V., Keech, A., et al (2010). Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia: clinical and experimental diabetes and metabolism, 54(2), 280-290. [More Information]
  • Goldstein, D., Gainford, M., Brown, C., Tebbutt, N., Ackland, S., van Hazel, G., Jefford, M., Abdi, E., Selva-Nayagam, S., Gebski, V., Miller, D., et al (2010). Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemotherapy and Pharmacology, , 1-7. [More Information]
  • Lee, C., Lord, S., Stockler, M., Coates, A., Gebski, V., Simes, R. (2010). Historical cross-trial comparisons for competing treatments in advanced breast cancer - An empirical analysis of bias. European Journal of Cancer, 46(3), 541-548. [More Information]
  • Noushi, F., Spillane, A., Uren, R., Gebski, V. (2010). Internal mammary node metastasis in breast cancer: Predictive models to determine status & management algorithms. European Journal of Surgical Oncology, 36(1), 16-22. [More Information]
  • Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P., Volgger, B., Vergote, I., Pignata, S., Ferrero, A., Brown, C., et al (2010). Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse. Journal of Clinical Oncology, 28(20), 3323-3329. [More Information]
  • Tarnow-Mordi, W., Gebski, V. (2010). Procalcitonin in intensive care units: the PRORATA trial. The Lancet, 375(9726), 1605. [More Information]
  • Sundaresan, P., Yeghiaian-Alvandi, R., Gebski, V. (2010). Prognostic index to identify patients who may not benefit from whole brain radiotherapy for multiple brain metastases from lung cancer. Journal of Medical Imaging and Radiation Oncology, 54(1), 69-75. [More Information]
  • Janda, M., Gebski, V., Brand, A., Hogg, R., Jobling, T., Land, R., Manolitsas, T., McCartney, A., Nascimento, M., Neesham, D., Pather, S., et al (2010). Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial. Lancet Oncology, 11(8), 772-780.
  • Tebbutt, N., Cummins, M., Sourjina, T., Strickland, A., van Hazel, G., Ganju, V., Gibbs, D., Stockler, M., Gebski, V., Zalcberg, J. (2010). Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. British Journal of Cancer, 102(3), 475-481.
  • Lee, C., Stockler, M., Coates, A., Gebski, V., Lord, S., Simes, R. (2010). Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. British Journal of Cancer, 102(9), 1341-1347. [More Information]
  • Veness, M., Foote, M., Gebski, V., Poulsen, M. (2010). The Role of Radiotherapy Alone in Patients With Merkel Cell Carcinoma: Reporting the Australian Experience of 43 Patients. International Journal of Radiation: Oncology - Biology - Physics, 78(3), 703-709. [More Information]
  • Brown, A., Atyeo, J., Field, N., Cox, J., Bull, C., Gebski, V. (2009). Evaluation of patient preferences towards treatment during extended hours for patients receiving radiation therapy for the treatment of cancer: A time trade-off study. Radiotherapy and Oncology, 90(2), 247-252. [More Information]
  • Green, M., Francis, P., Gebski, V., Harvey, V., Karapetis, C., Chan, A., Snyder, R., Fong, A., Basser, R., Forbes, J. (2009). Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. Annals of Oncology, 20(11), 1813-1817. [More Information]
  • Spillane, A., Noushi, F., Cooper, R., Gebski, V., Uren, R. (2009). High-resolution lymphoscintigraphy is essential for recognition of the significance of internal mammary nodes in breast cancer. Annals of Oncology, 20(6), 977-984. [More Information]
  • Oddone, N., Morgan, G., Palme, C., Perera, L., Shannon, J., Wong, E., Gebski, V., Veness, M. (2009). Metastatic cutaneous squamous cell carcinoma of the head and neck: the Immunosuppression, Treatment, Extranodal spread, and Margin status (ITEM) prognostic score to predict outcome and the need to improve survival. Cancer, 115(9), 1883-1891. [More Information]
  • Tantipalakorn, C., Robertson, G., Marsden, D., Gebski, V., Hacker, N. (2009). Outcome and patterns of recurrence for International Federation of Gynecology and Obstetrics (FIGO) stages I and II squamous cell vulvar cancer. Obstetrics and Gynecology, 113(4), 895-901. [More Information]
  • Gill, G., Wetzig, N., Gebski, V., Stockler, M., Ung, O., Campbell, I., Simes, R. (2009). Sentinel-Lymph-Node-Based Management or Routine Axillary Clearance? One-Year Outcomes of Sentinel Node Biopsy Versus Axillary Clearance (SNAC): A Randomized Controlled Surgical Trial. Annals of Surgical Oncology, 16(2), 266-275. [More Information]
  • Wang, W., Do, V., Hogg, R., Wain, G., Brand, A., Bull, C., Stenlake, A., Gebski, V. (2009). Uterine papillary serous carcinoma: patterns of failure and survival. Australian and New Zealand Journal of Obstetrics and Gynaecology, 49(4), 419-425. [More Information]
  • Obermair, A., Gebski, V., Frumovitz, M., Soliman, P., Schmeler, K., Levenback, C., Ramirez, P. (2008). A phase III randomized clinical trial comparing laparoscopic or robotic radical hysterectomy with abdominal radical hysterectomy in patients with early stage cervical cancer. Journal of Minimally Invasive Gynecology, 15(5), 584-588. [More Information]
  • Nowak, A., Cebon, J., Hargreaves, C., Dhillon, H., Findlay, M., Gebski, V., Stockler, M. (2008). Assessment of health-related quality of life and patient benefit as outcome measures for clinical trials in hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 4, 55-67.
  • Veness, M., Chong, L., Tiver, K., Gebski, V. (2008). Basal cell carcinoma of the nose: An Australian and New Zealand Radiation Oncology patterns-of practice study. Journal of Medical Imaging and Radiation Oncology, 52, 382-393. [More Information]
  • Smith, M., Gill, P., Wetzig, N., Sourjina, T., Gebski, V., Ung, O., Campbell, I., Kollias, J., Coskinas, X., Macphee, A., Simes, R., Stockler, M., et al (2008). Comparing patients' and clinicians' assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial). Breast Cancer Research and Treatment, Online (117)((1)), 1 (99)-11 (109). [More Information]
  • Shakespeare, T., Gebski, V., Tang, J., Lim, K., Lu, J., Zhang, X., Jiang, G. (2008). Influence of the Way Results Are Presented on Research Interpretation and Medical Decision Making: The PRIMER Collaboration Randomized Studies. Medical Decision Making: an international journal, 28(1), 127-137. [More Information]
  • Agustin, C., Grand, M., Gebski, V., Turner, S. (2008). Radiation therapists' perspective on barriers to clinical trials research. Journal of Medical Imaging and Radiation Oncology, 52(2), 178-182. [More Information]
  • Brunnberg, L., Smith, J., Hannon, R., Gebski, V., Cullis-Hill, D. (2007). A comparator study of pentosan polysulfate and carprofen on the clinical signs of pain and lameness in osteoarthritis [Eine Vergleichsstudie über Pentosanpolysulfat und Carprofen über die Klinischen Syptome Schmerz und Lahmheit bei Osteoarthritis]. Kleintier-Praxis, 52(3), 133-142.
  • Findlay, M., Storey, D., Gebski, V., Hargreaves, C., Cullingford, G., Boyer, M., Trotter, J., Archer, S., Davidson, A., Johnston, P., Yuen, J., Dhillon, H., et al (2007). A pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer: Australasian Gastrointestinal Trials Group study 9601. ANZ Journal of Surgery, 77(4), 247-252.
  • Nordsmark, M., Eriksen, J., Gebski, V., Alsner, J., Horsman, M., Overgaard, J. (2007). Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiotherapy and Oncology, 83(3), 389-397.
  • Tai, B., De Stavola, B., de Gruttola, V., Gebski, V., Machin, D. (2007). First-event or marginal estimation of cause-specific hazards for analysing correlated multivariate failure-time data? Statistics in Medicine, Published online 5 June 2007(28), 922-936. [More Information]
  • Keech, A., Pike, R., Granger, R., Gebski, V. (2007). Interpreting the results of a clinical trial. Medical Journal of Australia, 186(9), 318-319. [More Information]
  • Lin, C., Turner, S., Mai, T., Kneebone, A., Gebski, V. (2007). Late rectal and urinary toxicity from conformal, dose-escalated radiation therapy for prostate cancer: A prospective study of 402 patients. Journal of Medical Imaging and Radiation Oncology, 51(6), 578-583. [More Information]
  • Ahern, V., Koh, E., Gebski, V., Sathiyaseelan, Y. (2007). Paediatric medulloblastoma: Patterns of care and radiotherapy quality assurance in Australia. Journal of Medical Imaging and Radiation Oncology, 51(5), 458-464. [More Information]
  • Tinker, A., Gebski, V., Fitzharris, B., Buck, M., Stuart-Harris, R., Beale, P., Goldrick, A., Rischin, D. (2007). Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel-ANZGOG 02-01. Gynecologic Oncology, 104(3), 647-653. [More Information]
  • Wilcken, N., Gebski, V., Pike, R., Keech, A. (2007). Putting results of a clinical trial into perspective. Medical Journal of Australia, 186(7), 368-370. [More Information]
  • Ahern, V., Boyages, J., Gebski, V., Moon, D., Wilcken, N. (2007). Selective Mastectomy in the Management of Locally Advanced Breast Cancer. International Journal of Radiation: Oncology - Biology - Physics, 68. [More Information]
  • Gebski, V., Byth Wilson, K., Langlands, A. (2007). Statistical rigour is essential to clinical prediction. ANZ Journal of Surgery, 77(7), 597-598. [More Information]
  • Gebski, V., Burmeister, B., Smithers, B., Foo, K., Zalcberg, J., Simes, R. (2007). Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncology, 8(3), 226-234. [More Information]
  • Matsuura, Y., Robertson, G., Marsden, D., Soo-Nyung, K., Gebski, V., Hacker, N. (2007). Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecologic Oncology, 104(2), 406-410. [More Information]
  • Walleser, S., Griffiths, A., Lord, S., Howard, K., Solomon, M., Gebski, V. (2007). What is the value of computered tomography colonography in patients screening positive for fecal occult blood? A systematic review and economic evaluation. Clinical Gastroenterology and Hepatology, 5(12), 1439-1446. [More Information]
  • Wilcken, N., Gebski, V., Keech, A., Pike, R. (2007). Words, Words, Words. Medical Journal of Australia, 187(4), 256-256.
  • Stockler, M., Sourjina, T., Harvey, V., Frances, P., Byrne, M., van Hazel, G., Fitzharris, B., Ackland, S., Finch, K., Lindsay, D., Gebski, V., Simes, R., Coates, A., et al (2006). A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment. Breast Cancer Research and Treatment, 100(Supplement 1), S278-S278.
  • Shakespeare, T., Gebski, V., Thiagarajan, A., Lu, J. (2006). Development of a spreadsheet for the calculation of new tools to improve the reporting of the results of medical research. Medical Informatics and the Internet in Medicine, 31(2), 121-127. [More Information]
  • Jones, M., Onslow, M., Packman, A., Gebski, V. (2006). Guidelines for statistical analysis of percentage of syllables stuttered data. Journal of Speech, Language, and Hearing Research, 49(4), 867-878. [More Information]
  • Gill, P., Gebski, V., Wetzig, N., Ung, O., Campbell, I., Collins, J., Sourjina, T., Coskinas, X., Stockler, M., Simes, R. (2006). Sentinel node (SN) based management causes less arm swelling and better quality of life than routine axillary clearance (AC): 1 year outcomes of the SNAC trial. Breast Cancer Research and Treatment, 100(Supplement 1), S14-S14.
  • Cebon, J., Hargreaves, C., Stockler, M., Boyer, M., Nowak, A., Dhillon, H., Gebski, V., Dickman, B., Findlay, M., Poon, A., et al (2006). Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. British Journal of Cancer, 95(7), 853-861. [More Information]
  • Gebski, V., Lagleva, M., Keech, A., Simes, R., Langlands, A. (2006). Survival Effects of Postmastectomy Adjuvant Radiation Therapy Using Biologically Equivalent Doses: A Clinical Perspective - [Response]. National Cancer Institute. Journal, 98(17), 1021-1022.
  • Gebski, V., Lagleva, M., Keech, A., Simes, R., Langlands, A. (2006). Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective. National Cancer Institute. Journal, 98(1), 26-38. [More Information]
  • Dwyer, M., Gebski, V., Jayamohan, J. (2006). The bottom line: outcomes after conservation treatment in anal cancer. Journal of Medical Imaging and Radiation Oncology, 50(1), 46-51. [More Information]
  • Nordsmark, M., Loncaster, J., Aquino-Parsons, C., Chou, S., Gebski, V., West, C., Lindegaard, J., Havsteen, H., Davidson, S., Hunter, R., et al (2006). The prognostic value of pimonidazole and tumour pO(2) in human cervix carcinomas after radiation therapy: A prospective international multi-center study. Radiotherapy and Oncology, 80(2), 123-131. [More Information]
  • Matsuura, Y., Robertson, G., Marsden, D., Kim, S., Gebski, V., Hacker, N. (2006). Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecologic Oncology, 104(2), 406-410. [More Information]
  • Janda, M., Gebski, V., Forder, P., Jackson, D., Williams, G., Obermair, A. (2006). Total laparoscopic versus open surgery for stage 1 endometrial cancer: The LACE randomized controlled trial. Contemporary Clinical Trials, 27(4), 353-363. [More Information]
  • Veness, M., Foroudi, F., Gebski, V., Timms, I., Sathiyaseelan, Y., Vachan, B., Tiver, K. (2006). Use of topical misoprostol to reduce radiation-induced mucositis: Results of a randomized, double-blind, placebo-controlled trial. Journal of Medical Imaging and Radiation Oncology, 50(5), 468-474. [More Information]
  • Veness, M., Gebski, V., Morgan, G. (2005). Adjuvant locoregional radiotherapy as best practice in patients with Merkel cell carcinoma of the head and neck. Head and Neck, 27(3), 208-216. [More Information]
  • Forder, P., Gebski, V., Keech, A. (2005). Allocation concealment and blinding [reply]. Medical Journal of Australia, 183(3), 165-166.
  • Forder, P., Gebski, V., Keech, A. (2005). Allocation concealment and blinding: when ignorance is bliss. Medical Journal of Australia, 182(2), 87-89. [More Information]
  • Veness, M., Morgan, G., Gebski, V., Sathiyaseelan, Y. (2005). Anterior tongue cancer and the incidence of cervical lymph node metastases with increasing tumour thickness: should elective treatment to the neck be standard practice in all patients? ANZ Journal of Surgery, 75(3), 101-105. [More Information]
  • Heritier, S., Gebski, V., Pillai, A. (2005). Dynamic balancing randomization in controlled clinical trials. Statistics in Medicine, 24(24), 3729-3741. [More Information]
  • Shakespeare, T., Thiagarajan, A., Gebski, V. (2005). Evaluation of the quality of radiotherapy randomized trials for painful bone metastases. Cancer, 103(9), 1976-1981. [More Information]
  • Veness, M., Perera, L., McCourt, J., Shannon, J., Hughes, T., Morgan, G., Gebski, V. (2005). Merkel cell carcinoma: improved outcome with adjuvant radiotherapy. ANZ Journal of Surgery, 75(5), 275-281. [More Information]
  • Foo, K., Gebski, V., Yeghiaian-Alvandi, R., Foroudi, F., Vachan, B. (2005). Outcome following radiotherapy for loco-regionally recurrent non-small cell lung cancer. Journal of Medical Imaging and Radiation Oncology, 49(2), 108-112. [More Information]
  • Wetzig, N., Gill, P., Ung, O., Collins, J., Kollias, J., Gillett, D., Gebski, V., Greig, C., Ray, A., Stockler, M. (2005). Participation in the RACS sentinel node biopsy versus axillary clearance trial. ANZ Journal of Surgery, 75(3), 98-100. [More Information]
  • Lataifeh, I., Marsden, D., Robertson, G., Gebski, V., Hacker, N. (2005). Presenting symptoms of epithelial ovarian cancer. Australian and New Zealand Journal of Obstetrics and Gynaecology, 45(3), 211-4. [More Information]
  • Jones, M., Onslow, M., Packman, A., Williams, S., Ormond, T., Schwarz, I., Gebski, V. (2005). Randomised controlled trial of the Lidcombe programme of early stuttering intervention. BMJ: British Medical Journal, 331(7518), 659-661. [More Information]
  • Burmeister, B., Smithers, B., Gebski, V., Fitzgerald, L., Simes, R., Devitt, P., Ackland, S., Gotley, D., Joseph, D., Millar, J., Walpole, E., et al (2005). Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology, 6(9), 659-668. [More Information]
  • Veness, M., Morgan, G., Palme, C., Gebski, V. (2005). Surgery and Adjuvant Radiotherapy in Patients with Cutaneous Head and Neck Squamous Cell Carcinoma Metastatic to Lymph Nodes: Combined Treatment Should be Considered Best Practice. The Laryngoscope, 115(5), 870-875. [More Information]
  • Qian, M., Wang, D., Watkins, W., Gebski, V., Yan, Y., Li, M., Chen, Z. (2005). The effects of iodine on intelligence in children: a meta-analysis of studies conducted in China. Asia Pacific Journal of Clinical Nutrition, 14(1), 32-42. [More Information]
  • Keech, A., Wonders, S., Cook, D., Gebski, V. (2004). Balancing the outcomes: reporting adverse events. Medical Journal of Australia, 181(4), 215-218.
  • Gebski, V. (2004). Book Review: Statistics in Clinical Oncology. Statistics in Medicine, 23(13), 2151-2153.
  • Chin, Y., Jayamohan, J., Clouston, P., Gebski, V., Vachan, B. (2004). Driving and Patients with Brain Tumours: a postal survey of Neurosurgeons, Neurologists and Radiation Oncologists. Journal of Clinical Neuroscience, 11(5), 471-474. [More Information]
  • Byth Wilson, K., Gebski, V. (2004). Factorial designs: a graphical aid for choosing study designs accounting for interaction. Clinical Trials, 1(3), 315-325.
  • Seale, J., Gebski, V., Keech, A. (2004). Generalising the results of trials to clinical practice. Medical Journal of Australia, 181(10), 558-560.
  • O'Connell, R., Gebski, V., Keech, A. (2004). Making Sense Of Trial Results: Outcomes And Estimation. Medical Journal of Australia, 180(3), 128-130.
  • Lord, S., Gebski, V., Keech, A. (2004). Multiple Analyses In Clinical Trials: Sound Science Or Data Dredging? Medical Journal of Australia, 181(8), 452-454.
  • Tarnow-Mordi, W., Gebski, V., Cust, A. (2004). Noninvasive Ventilation: To the Editor. New England Journal of Medicine, 351(12), 1257-1257. [More Information]
  • Cook, D., Gebski, V., Keech, A. (2004). Subgroup analysis in clinical trials. Medical Journal of Australia, 180(6), 289-291.
  • Simes, R., Gebski, V., Keech, A. (2004). Subgroup analysis: application to individual patient decisions. Medical Journal of Australia, 180(9), 467-469. [More Information]
  • Kneebone, A., Gebski, V., Hogendoorn, N., Turner, S. (2003). A randomised trial evaluating rigid immobilization for pelvic irradiation. International Journal of Radiation: Oncology - Biology - Physics, 56(4), 1105-1111.
  • Veness, M., Morgan, G., Sathiyaseelan, Y., Gebski, V. (2003). Anterior tongue cancer: age is not a predictor of outcome and should not alter treatment. ANZ Journal of Surgery, 73(11), 899-904.
  • Kneebone, A., Turner, S., Berry, M., Vachan, B., Gebski, V. (2003). Australian prostate-specific antigen outcome and toxicity following radiation therapy for localized prostate cancer. Journal of Medical Imaging and Radiation Oncology, 47(4), 422-427.
  • Burgess, D., Gebski, V., Keech, A. (2003). Baseline data in clinical trials. Medical Journal of Australia, 11, 105-107.
  • Kirby, A., Gebski, V., Keech, A. (2003). Determining the sample size in a clinical trial [in reply]. Medical Journal of Australia, 178(7), 358-358.
  • Vachan, B., Gebski, V., Keech, A. (2003). Flow of participants in randomised studies. Medical Journal of Australia, 178, 347-349.
  • Heritier, S., Gebski, V., Keech, A. (2003). Inclusion of patients in clinical trial analysis: the intention-to-treat principle. Medical Journal of Australia, 11, 438-440.
  • Keech, A., Gebski, V. (2003). Managing the resource demands of a large sample size in clinical trials: can you succeed with fewer subjects. Medical Journal of Australia, 178(7), 356-357.
  • Hornbuckle, J., Culjak, G., Jarvis, E., Gebski, V., Coates, A., Mann, G., Kefford, R. (2003). Patterns of metastases in familial and non-familial melanoma. Melanoma Research: a journal for basic, translational and clinical research in melanoma, 13(1), 105-109.
  • Hague, W., Gebski, V., Keech, A. (2003). Recruitment to randomised studies. Medical Journal of Australia, 178(11), 579-581.
  • Babington, S., Veness, M., Vachan, B., Gebski, V., Morgan, G. (2003). Squamous cell carcinoma of the lip: is there a role for adjuvant radiotherapy in improving local control following incomplete or inedequate excision? ANZ Journal of Surgery, 73(8), 621-625.
  • Gebski, V., Keech, A. (2003). Statistical methods in clinical trials. Medical Journal of Australia, 11, 182-184.
  • Hyam, D., Conway, R., Sathiyaseelan, Y., Gebski, V., Morgan, G., Walker, D., Veness, M. (2003). Tongue cancer: do patients younger than 40 do worse? Australian Dental Journal, 48(1), 50-54.
  • Barton, M., Jacob, S., Gebski, V. (2003). Utility-adjusted analysis of the cost of palliative radiotherapy for bone metastases. Journal of Medical Imaging and Radiation Oncology, 47(3), 274-278.
  • Smith, J., Shannon, R., Brunnberg, L., Gebski, V., Cullis-Hill, D. (2002). A multicentre clinical study of the efficacy of sodium pentosan polysulfate and carprofen in canine osteoarthritis (osteoarthrosis). Norsk Veterinaertidsskrift, , 123-130.
  • Lewis, J., Beldham-Collins, R., Gebski, V. (2002). Changes in stress perceptions of radiation therapists following a debriefing program. The Radiographer, 49(3), 133-135.
  • Langlands, A., Gebski, V., Hirsch, D., Tattersall, M. (2002). Delay in the clinical diagnosis of breast cancer: estimating its effect on prognosis, with particular reference to medical litigation. The Breast, 11(5), 386-393.
  • Kirby, A., Gebski, V., Keech, A. (2002). Determining the sample size in a clinical trial. Medical Journal of Australia, , 256-257.
  • Finnie, J., Blumbergs, P., Manavis, J., Utteridge, T., Gebski, V., Davies, R., Vernon-Roberts, B., Kuchel, T. (2002). Effect of long-term mobile communication microwave exposure on vascular permeability in mouse brain. Pathology, 34(4), 344-347.
  • Shakespeare, T., Dwyer, M., Mukherjee, R., Yeghiaian-Alvandi, R., Gebski, V. (2002). Estimating risks of radiotherapy complications as part of informed consent: the high degree of variability between radiation oncologists may be related to experience. International Journal of Radiation: Oncology - Biology - Physics, 54(3), 647-653.
  • Cuzick, J., Forbes, J., Edwards, R., Baum, M., Cawthorn, S., Coates, A., Hamed, H., Howell, A., Powels, T., Dhillon, H., Gebski, V., Simes, R. (2002). First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial. The Lancet, 360(9336), 817-824.
  • Cuzjik, J., Dhillon, H., Gebski, V., Simes, R. (2002). First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. The Lancet, 360(9336), 817-824.
  • Utteridge, T., Gebski, V., Finnie, J., Vernon-Roberts, B., Kuchel, T. (2002). Long-term exposure of Eu-Pim 1 transgenic mice to 898.4 MHz microwaves does not increase lymphoma incidence. Radiation Research, 158(3), 357-364.
  • Keech, A., Gebski, V. (2002). Managing the resource demands of a large sample size in clinical trials: can you succeed with fewer subjects? Medical Journal of Australia, 177(8), 437-439.
  • Tai, B., White, I., Gebski, V., Machin, D. (2002). On the issue of 'multiple' first failures in competing risks analysis. Statistics in Medicine, 21(15), 2243-2255. [More Information]
  • Veness, M., Chua, M., Morgan, G., Shakespeare, T., Hehir, A., Gebski, V., Vachan, B., Tiver, K. (2002). Parotid lymph-node metastases from cutaneous squamous-cell carcinomas: Treatment outcome and prognostic factors following surgery and adjuvant radiotherapy. Journal of Medical Imaging and Radiation Oncology, 46(2), 174-179.
  • Liu, P., Gebski, V., Turner, L., Conway, A., Wishart, S., Handelsman, D. (2002). Predicting pregnancy and spermatogenesis by survival analysis during gonadotrophin treatment of gonadotrophin-deficient infertile men. Human Reproduction, 17(3), 625-633.
  • Foroudi, F., Bull, C., Gebski, V. (2002). Radiation Therapy for Cervix Carcinoma: Benefits of Individualized Dosimetry. Clinical Oncology, 14(1), 43-49.
  • Beller, E., Gebski, V., Keech, A. (2002). Randomisation in clinical trials. Medical Journal of Australia, 177(10), 565-567.
  • Tay, E., Grant, P., Gebski, V., Hacker, N. (2002). Secondary Cytoreduction Surgery for Recurrent Epithelial Ovarian Cancer. Obstetrics and Gynecology, 100(6), 1359-1360.
  • Tay, E., Grant, P., Gebski, V., Hacker, N. (2002). Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstetrics and Gynecology, 99(6), 1008-1013.
  • Langlands, A., Gebski, V. (2002). Sharp v Port Kembla RSL club: establishing causation of laryngeal cancer by environmental tobacco smoke. Medical Journal of Australia, 176(9), 448-448.
  • Brighton, J., Gebski, V., Keech, A. (2002). Specifying interventions in a clinical trial. Medical Journal of Australia, , 281-282.
  • Gebski, V., Marschner, C., Keech, A. (2002). Specifying objectives and outcomes for clinical trials. Medical Journal of Australia, 176(10), 491-492.
  • Jones, M., Gebski, V., Onslow, M., Packman, A. (2002). Statistical power in stuttering research: a tutorial. Journal of Speech, Language, and Hearing Research, 45(2), 243-255.
  • Hu, G., Walls, R., Bass, D., Bullock, R., Grayson, D., Jones, M., Gebski, V. (2002). The Chinese herbal formulation Biminne in management of perennial allergic rhinitis: a randomized, double-blind, placebo-controlled, 12-week clinical trial. Annals of Allergy, Asthma, and Immunology, 88(5), 478-487.
  • Grogan, M., Rangan, A., Gebski, V., Boyages, J. (2002). The value of follow-up of patients with early breast cancer treated with conservative surgery and radiation therapy. The Breast, 11(2), 163-169.
  • Smith, J., Hannon, R., Brunnberg, L., Gebski, V., Cullis-Hill, D. (2001). A randomised, double-blind, comparator clinical study of the efficacy of sodium pentosan polysulfate injection and carprofen capsules in arthritic dogs. Osteoarthritis and Cartilage, 9(Supplement 2), S21-S22.
  • Lumley, T., Simes, R., Gebski, V., Hudson, H. (2001). Combining components of quality of life to increase precision and evaluate trade-offs. Statistics in Medicine, 20(21), 3231-3249.
  • Lumley, T., Simes, R., Gebski, V., Hudson, M. (2001). Combining components of quality of life to increase precision and evaluate trade-offs. Statistics in Medicine, 20, 3231-3249.
  • Toner, G., Stockler, M., Boyer, M., Jones, M., Thomson, D., Harvey, V., Olver, I., Dhillon, H., McMullen, A., Gebski, V., Levi, J., Simes, R. (2001). Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. The Lancet, 357(9528), 739-745.
  • Gebski, V., Tai, B., Machin, D., White, I. (2001). Competing risks analysis of patients with osteosarcoma: a comparison of four different approaches. Statistics in Medicine, 20, 661-684.
  • Tai, B., Machin, D., White, I., Gebski, V. (2001). Competing risks analysis of patients with osteosarcoma: a comparison of four different approaches. Statistics in Medicine, 20(5), 661-684.
  • Jones, M., Gebski, V., Onslow, M., Packman, A. (2001). Design of randomized controlled trials principles and methods applied to a treatment for early stuttering. Journal of Fluency Disorders, 26, 247-267.
  • Jones, M., Gebski, V., Onslow, M., Packman, A. (2001). Design of randomized controlled trials: Principles and methods applied to a treatment for early stuttering. Journal of Fluency Disorders, 26(4), 247-267.
  • Gebski, V., Finnie, J., Blumbergs, P., Manavis, J., Utteridge, T., Swift, J., Vernon-Roberts, B., Kuchel,, T. (2001). Effect of global system for mobile communication (gsm)-like radiofrequency fields on vascular permeability in mouse brain. Pathology, 33, 338-340.
  • Finnie, J., Blumbergs, P., Manavis, J., Utteridge, T., Gebski, V., Swift, J., Vernon-Roberts, B., Kuchel, T. (2001). Effect of Global System for Mobile Communication (GSM)-Like Radiofrequency Fields on Vascular Permeability in Mouse Brain. Pathology, 33(3), 338-340.
  • Gebski, V., Finnie, J., Van, D., Manavis, J., Summersides, G., Blumbergs, P. (2001). Effect of impact on different regions of the head of lambs. Journal of Comparative Pathology, 124, 159-164.
  • Finnie, J., Van Den Heuvel, C., Gebski, V., Manavis, J., Summersides, G., Blumbergs, P. (2001). Effect of Impact on Different Regions of the Head of Lambs. Journal of Comparative Pathology, 124(2-3), 159-164.
  • Gebski, V., Veness, M., Simes, R., Shakespeare, T. (2001). Improving interpretation of clinical studies by use of confidence intervals, clinical significnce cureves, and risk analysis. The Lancet, 357, 1349-1353.
  • Shakespeare, T., Gebski, V., Veness, M., Simes, R. (2001). Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk-benefit contours. The Lancet, 357(9265), 1349-1353.
  • Turner, S., Gruenewald, S., Spry, N., Gebski, V. (2001). Less pain does equal better quality following stronutium-89 therapy for mestatic prostate cancer. British Journal of Cancer, 84 (3), 297-302.
  • Turner, S., Gruenewald, S., Spry, N., Gebski, V. (2001). Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. British Journal of Cancer, 84(3), 297-302.
  • Gray, B., Van Hazel, G., Hope,, M., Burton, M., Moroz, P., Anderson, J., Gebski, V. (2001). Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Annals of Oncology, 12(12), 1711-1720.
  • Gebski, V., Gray, B., Van, H., Hope,, M., Burton, M., Moroz, P., Anderson, J. (2001). Randomised trial of SIR-spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastses from primary large bowel cancer. Annals of Oncology, 12, 1711-1720.
  • Gebski, V., Beller, E., Keech, A. (2001). Randomized controlled trails: elements of a good study. Medical Journal of Australia, 175, 272-274.
  • Ghersi, D., Gebski, V., Keech, A. (2001). Scientific background and rationale for a randomised controlled trial. Medical Journal of Australia, 175(7), 386-386.
  • Keech, A., Gebski, V. (2001). Selecting participants for clinical trials. Medical Journal of Australia, 175(9), 490-491.
  • Dealney, G., Gebski, V., Langlands, A. (2001). To BTE or Not BTE: That is the Question. Clinical Oncology, 13(4), 311-312.

Conferences

  • Shakespeare, T., Lu, J., Tang, J., Lim, K., Mukherjee, R., Back, M., Gebski, V. (2007). Choosing my treatment: incorporating informational and decision-making needs into a Preference Compass. RANZCR, 58th Annual Scientific Meeting.
  • Nordsmark, M., Gebski, V. (2006). Assays directed to assess tumor hypoxiain human tumor and their implications as prognostic and predictive assays. ICTR 3rd International Conference on Translational Research.
  • Nordsmark, M., Gebski, V., Loncaster, J., Aquino-Parsons, C., Chou, S., West, C., Lindegaard, J., Havsteen, H., Davidson, S., Raleigh, J., Overgaard, J. (2006). The Prognostic Value of Pimonidazole and Tumor pO2 in Human Cervix Carcinomas after Radiation Therapy: An International Multi-Centre Study. ICTR 3rd International Conference on Translational Research.
  • Gebski, V., Lagleva, M., Simes, R., Keech, A., Langlands, A. (2005). Adjuvant Radiotherapy in Early Breast Cancer: The Clinical Utility of Published Meta-Analysis. RANZCR, 55th Annual Scientific Meeting.
  • Gebski, V. (2005). Calendar and Event Based Clinical Trial Designs and Surrogate Outcomes. Cardiac Society of Australia and New Zealand.
  • Gebski, V., Heritier, S., Pillai, A., Luke, V., Simes, R., Keech, A. (2005). Computer modelling of adaptive randomisation schemes in large scale randomised controlled trials. 20th International Workshop on Statistical Modelling, Sydney, Australia: University of Western Sydney.
  • Gebski, V. (2005). The Results from a Meta-Analysis of Preoperative Therapy for Oesophageal cancer. Clinical Oncology Society of Australia.
  • Gebski, V., Vachan, B. (2004). Flexetrials an Introduction to Inform. Taiwan-Australian International Symposium on Clinical Trials.
  • Gebski, V., Vachan, B. (2004). Management of Oncology Trials and Co-operative Groups in Australia. Taiwan-Australian International Symposium on Clinical Trials.
  • Smithers, B., Burmeister, B., Fitzgerald, L., Gebski, V., Denham, J., Devitt, P., Ackland, S., Joseph, D., Millar, J., North, J., Walpole, E., et al (2003). A randomised controlled trial of surgery alone compared with chemoradiation and surgery: a focus on surgical outcomes. 56th Annual Cancer Symposium of the Society of Surgical Oncology.
  • Gebski, V. (2003). Clinical Trials and Tribulations. 43rd Annual Scientific Meeting International Dental Research Association Conference.
  • Burmeister, B., Smithers, B., Gebski, V., Fitzgerald, L., Devitt, P., Ackland, S., Joseph, D., Denham, J. (2003). Preoperative chemoradiation therapy for oesophageal cancer-results of the Australasian Study IG9401. 12th International Conference on Radiation Research (ICRR).
  • Cullingford, G., Findlay, M., Storey, D., Boyer, M., Trotter, J., Archer, S., Davidson, A., Johnston, P., Gebski, V., Dhillon, H. (2002). A phase II feasibility study of pre-operative and post-operative chemotherapy (epirubicin, cisplatin and 4FU (ECF)) in patients with advanced but operable gastric cancer: and Australasian Gastro-Intestinal Trials Group (AGITG) study (AG9601). 38th Annual Meeting of ASCO.
  • Burmeister, B., Smithers, B., Fitzgerald, L., Gebski, V., Devitt, P., Ackland, S., Joseph, M., Millar, J., Millar, J., Walpole, E., et al (2002). A randomized phase III trial of preoperative chemoradiation followed by surgery versus surgery alone for localized resectable cancer of the esophagus. 38th Annual Meeting of ASCO.
  • Wetzig, N., Gill, P., Ung, O., Collins, J., Kollias, J., Gillette, D., Gebski, V., Greig, C., Ray, A., Stockler, M. (2002). Eligibility and Choice in the royal Australiasian College of Surgeons "SNAC Trial" of Sentinel Node Biopsy versus axillary clearance in operable breast cancer. 3rd International Sentinel Node Congress.
  • Gray, B., Van Hazel, G., Anderson, J., Price, A., Moroz, P., Bower, G., Blackwell, A., Gebski, V. (2002). Randomised phase II trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone on advanced colorectal hepatic metastases. 38th Annual Meeting of ASCO.
  • Gebski, V., Simes, R. (2002). Survival plots for interpreting trial results. International Clinical Trials Symposium.
  • Delaney, G., Gebski, V., Jalaludin, B., Griffiths, B. (2001). Basic treatment equivalent (BTE) – a better measure of linear accelerator workload. ECCO 11. European Cancer Conference.
  • Hui, A., Barton, B., Gebski, V. (2001). Complications of Radiotherapy for Rectal Cancer A Systematic Review. Royal Australian & New Zealand College of Radiologists, 52nd Annual Scientific Meeting.
  • Chin, Y., Jayamohan, J., Gebski, V. (2001). Driving and Patients with Brain Tumours: A Postal Survey of Neurosurgeons, Neurologists and Radiation Oncologists in New South Wales. Royal Australian & New Zealand College of Radiologists, 52nd Annual Scientific Meeting.
  • Koh, E., Ahern, V., Sathiyaseelan, Y., Gebski, V. (2001). Radiotherapy Quality Assurance for Paediatric Medulloblastoma in Australia. Royal Australian & New Zealand College of Radiologists, 52nd Annual Scientific Meeting.
  • Dwyer, M., Gebski, V., Jayamohan, J. (2001). The Bottom Line: Outcomes following Conservation Therapy in Anal Cancer. Clinical Oncological Society of Australia.
  • Thompson, S., Turner, S., Gebski, V. (2001). The IPSS: A Better Way of Measuring Urinary Morbidity from Prostate Brachytherapy? Royal Australian & New Zealand College of Radiologists, 52nd Annual Scientific Meeting.
  • Shakespeare, T., Dwyer, M., Mukherjee, R., Yeghiaian-Alvandi, R., Gebski, V. (2001). Variability in estimating late normal tissue toxicity for patients receiving radiotherapy. Does experience influence whet we are telling our patients. ECCO 11. European Cancer Conference.

2014

  • Grimison, P., Stockler, M., Chatfield, M., Thomson, D., Gebski, V., Friedlander, M., Boland, A., Houghton, B., Gruney, H., Rosenthal, M., et al (2014). Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Annals of Oncology, 25(1), 143-148. [More Information]
  • Tran, B., Armstrong, B., Ebeling, P., English, D., Kimlin, M., van der Pols, J., Venn, A., Gebski, V., Whiteman, D., Webb, P., et al (2014). Effect of vitamin D supplementation on antibiotic use: a randomized controlled trial. The American Journal of Clinical Nutrition, 99(1), 156-161. [More Information]
  • Beumer, J., Gill, G., Campbell, I., Wetzig, N., Ung, O., Farshid, G., Uren, R., Stockler, M., Gebski, V. (2014). Sentinel node biopsy and large (≥3 cm) breast cancer. ANZ Journal of Surgery, 84(3), 117-120. [More Information]

2013

  • Lee, C., Simes, R., Brown, C., Gebski, V., Pfisterer, J., Swart, A., Berton-Rigaud, D., Plante, M., Skeie-Jensen, T., Vergote, I., Lord, S., et al (2013). A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. Annals of Oncology, 24(4), 937-943. [More Information]
  • Tebbutt, N., Parry, M., Zannino, D., Strickland, A., van Hazel, G., Pavlakis, N., Ganju, V., Mellor, D., Dobrovic, A., Gebski, V. (2013). Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. British Journal of Cancer, 108(4), 771-774. [More Information]
  • Najim, M., Cross, S., Gebski, V., Palme, C., Morgan, G., Veness, M. (2013). Early-stage squamous cell carcinoma of the lip: The Australian experience and the benefits of radiotherapy in improving outcome in high-risk patients after resection. Head and Neck, 35(10), 1426-1430. [More Information]
  • Blinman, P., Gainford, C., Donoghoe, M., Martyn, J., Bloomfield, P., Grant, P., Kichenadasse, G., Vaughan, M., Brand, A., Shannon, C., Gebski, V., Stockler, M., et al (2013). Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. Journal of Gynecologic Oncology, 24(4), 359-366. [More Information]
  • Noushi, F., Spillane, A., Uren, R., Cooper, R., Allwright, S., Snook, K., Gillett, D., Pearce, A., Gebski, V. (2013). High discordance rates between sub-areolar and peri-tumoural breast lymphoscintigraphy. European Journal of Surgical Oncology, 39(10), 1053-1060. [More Information]
  • Obermair, A., Janda, M., Gebski, V. (2013). Identification of doctors at risk of recurrent complaints: a national study of healthcare complaints in Australia. BMJ Quality and Safety, 22(10), 878. [More Information]
  • Carus, A., Gurney, H., Gebski, V., Harnett, P., Hui, R., Kefford, R., Wilcken, N., Ladekarl, M., von der Maase, H., Donskov, F. (2013). Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. Journal of Translational Medicine, 11(1), 1-10. [More Information]
  • Lee, C., Brown, C., Gralla, R., Hirsh, V., Thongprasert, S., Tsai, C., Tan, E., Ho, J., Chu, D., Zaatar, A., Gebski, V., et al (2013). Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis. National Cancer Institute. Journal, 105(9), 595-605. [More Information]
  • Wang, J., Palme, C., Wang, A., Morgan, G., Gebski, V., Veness, M. (2013). In patients with metastatic cutaneous head and neck squamous cell carcinoma to cervical lymph nodes, the extent of neck dissection does not influence outcome. The Journal of Laryngology and Otology, 127(Suppl. S1), S2-S7. [More Information]
  • Dignan, R., Keech, A., Gebski, V., Mann, K., Hughes, C. (2013). Is home warfarin self-management effective? Results of the randomised Self-Management of Anticoagulation Research Trial. International Journal of Cardiology, 168(6), 5378-5384. [More Information]
  • Fox, P., Hudson, M., Brown, C., Lord, S., Gebski, V., de Souza, P., Lee, C. (2013). Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. British Journal of Cancer, 109(1), 147-153. [More Information]
  • Tran, B., Armstrong, B., McGeechan, K., Ebeling, P., English, D., Kimlin, M., Lucas, R., van der Pols, J., Venn, A., Gebski, V., et al (2013). Predicting vitamin D deficiency in older Australian adults. Clinical Endocrinology, 79(5), 631-640. [More Information]
  • Hacker, N., Barlow, E., Scurry, J., Gebski, V., Farrell, R., Robertson, G., Friedlander, M., Jackson, M. (2013). Primary surgical management with tailored adjuvant radiation for stage IB2 cervical cancer. Obstetrics and Gynecology, 121(4), 765-772. [More Information]
  • Wang, A., Palme, C., Wang, J., Morgan, G., Gebski, V., GILCHRIST, J., Veness, M. (2013). Quality of life assessment in patients treated for metastatic cutaneous squamous cell carcinoma of the head and neck. The Journal of Laryngology and Otology, 127(Suppl. S2), S39-S47. [More Information]
  • Olver, I., Grimison, P., Chatfield, M., Stockler, M., Toner, G., Gebski, V., Harrup, R., Underhill, C., Kichenadasse, G., Singhal, N., Boland, A., McDonald, A., et al (2013). Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. Supportive Care in Cancer, 21(6), 1561-1568. [More Information]
  • Graves, N., Janda, M., Merollini, K., Gebski, V., Obermair, A. (2013). The cost-effectiveness of total laparoscopic hysterectomy compared to total abdominal hysterectomy for the treatment of early stage endometrial cancer. BMJ Open, 3(4), 1-5. [More Information]
  • Garner, A., Fearnside, M., Gebski, V. (2013). The study protocol for the Head Injury Retrieval Trial (HIRT): a single centre randomised controlled trial of physician prehospital management of severe blunt head injury compared with management by paramedics. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 21, 1-8. [More Information]
  • Lee, C., Gebski, V., Coates, A., Veillard, A., Harvey, V., Tattersall, M., Byrne, M., Brigham, B., Forbes, J., Simes, R. (2013). Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone. SpringerPlus, 2(391), 1-10. [More Information]
  • Small, K., Kelly, C., Beldham-Collins, R., Gebski, V. (2013). Whole breast and excision cavity radiotherapy plan comparison: Conformal radiotherapy with sequential boost versus intensity-modulated radiation therapy with a simultaneously integrated boost. Journal of Medical Radiation Sciences, 60(1), 16-24. [More Information]

2012

  • Venkateswaran, L., Butow, P., Jansen, J., Wilcken, N., WONG, M., Hui, R., Szonyi, G., Gebski, V., Naganathan, V., Horvath, L., Tattersall, M. (2012). Decision making in older patients with advanced cancer: Does doctor know best? Medical Journal of Australia, 196(1), 35-39. [More Information]
  • Weickhardt, A., Price, T., Chong, G., Gebski, V., Pavlakis, N., Johns, T., Azad, A., Skrinos, E., Fluck, K., Dobrovic, A., et al (2012). Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. Journal of Clinical Oncology, 30(13), 1505-1512. [More Information]
  • Sullivan, D., Olsson, A., Scott, R., Kim, J., Xue, A., Gebski, V., Wasserman, S., Stein, E. (2012). Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA: The Journal of the American Medical Association, 308(23), 2497-2506. [More Information]
  • Baker, J., Obermair, A., Gebski, V., Janda, M. (2012). Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: A meta-analysis and systematic review of the literature. Gynecologic Oncology, 125(1), 263-270. [More Information]
  • Coburn, N., Beldham-Collins, R., Westling, J., Trovato, J., Gebski, V. (2012). Evaluation of flexible and rigid (class solution) radiation therapy conformal prostate planning protocols. Medical Dosimetry, 37(1), 5-8. [More Information]
  • Wagner, U., Marth, C., Largillier, R., Kaern, J., Brown, C., Heywood, M., Bonaventura, T., Vergote, I., Piccirillo, M., Fossati, R., et al (2012). Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. British Journal of Cancer, 107(4), 588-591. [More Information]
  • Brundage, M., Gropp, M., Mefti, F., Mann, K., Lund, B., Gebski, V., Wolfram, G., Reed, N., Pignata, S., Ferrero, A., Brown, C., et al (2012). Health-related quality of life in recurrent platinum-sensitive ovarian cancer - results from the CALYPSO trial. Annals of Oncology, 23(8), 2020-2027. [More Information]
  • Obermair, A., Janda, M., Baker, J., Kondalsamy-Chennakesavan, S., Brand, A., Hogg, R., Jobling, T., Land, R., Manolitsas, T., Nascimento, M., Gebski, V., et al (2012). Improved surgical safety after laparoscopic compared to open surgery for apparent early stage endometrial cancer: Results from a randomised controlled trial. European Journal of Cancer, 48(8), 1147-1153. [More Information]
  • Lord, S., Marinovich, M., Patterson, J., Wilcken, N., Kiely, B., Gebski, V., Crossing, S., Roder, D., Gattellari, M., Houssami, N. (2012). Incidence of metastatic breast cancer in an Australian population-based cohort of women with non-metastatic breast cancer at diagnosis. Medical Journal of Australia, 196(11), 688-692. [More Information]
  • Howle, J., Hughes, T., Gebski, V., Veness, M. (2012). Merkel cell carcinoma: An Australian perspective and the importance of addressing the regional lymph nodes in clinically node-negative patients. Journal Of The American Academy Of Dermatology, 67(1), 33-40. [More Information]
  • Gebski, V., Ellingson, K., Edwards, J., Jernigan, J., Kleinbaum, D. (2012). Modelling interrupted time series to evaluate prevention and control of infection in healthcare. Epidemiology and Infection, 140(12), 2131-2141. [More Information]
  • Kifley, A., Heller, G., Beath, K., Bulger, D., Ma, J., Gebski, V. (2012). Multilevel latent variable models for global health-related quality of life assessment. Statistics in Medicine, 31(11-12), 1249-1264. [More Information]
  • Wang, J., Palme, C., Morgan, G., Gebski, V., Wang, A., Veness, M. (2012). Predictors of outcome in patients with metastatic cutaneous head and neck squamous cell carcinoma involving cervical lymph nodes: Improved survival with the addition of adjuvant radiotherapy. Head and Neck, 34(11), 1524-1528. [More Information]
  • Tran, B., Armstrong, B., Carlin, J., Ebeling, P., English, D., Kimlin, M., Rahman, B., van der Pols, J., Venn, A., Gebski, V., et al (2012). Recruitment and Results of a Pilot Trial of Vitamin D Supplementation in the General Population of Australia. Journal of Clinical Endocrinology and Metabolism, 97(12), 4473-4480. [More Information]
  • Kondalsamy-Chennakesavan, S., Janda, M., Gebski, V., Baker, J., Brand, A., Hogg, R., Jobling, T., Land, R., Manolitsas, T., Nascimento, M., et al (2012). Risk factors to predict the incidence of surgical adverse events following open or laparoscopic surgery for apparent early stage endometrial cancer: Results from a randomised controlled trial. European Journal of Cancer, 48(14), 2155-2162. [More Information]
  • Goldstein, D., Spry, N., Cummins, M., Brown, C., van Hazel, G., Carroll, S., Selva-Nayagam, S., Borg, M., Ackland, S., Wratten, C., Hruby, G., Horvath, L., Gebski, V., et al (2012). The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. British Journal of Cancer, 106(1), 61-69. [More Information]
  • Nicklin, J., Janda, M., Gebski, V., Jobling, T., Land, R., Manolitsas, T., McCartney, A., Nascimento, M., Perrin, L., Baker, J., et al (2012). The utility of serum CA-125 in predicting extra-uterine disease in apparent early stage endometrial cancer. International Journal of Cancer, 131(4), 885-890. [More Information]

2011

  • Lee, C., Hudson, M., Stockler, M., Coates, A., Ackland, S., Gebski, V., Lord, S., Friedlander, M., Boyle, F., Simes, R. (2011). A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. Breast Cancer Research and Treatment, 129(2), 467-476. [More Information]
  • Stockler, M., Harvey, V., Francis, P., Byrne, M., Ackland, S., Fitzharris, B., Van Hazel, G., Wilcken, N., Grimison, P., Nowak, A., Zannino, D., Gebski, V., Coates, A., et al (2011). Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. Journal of Clinical Oncology, 29(34), 4498-4504. [More Information]
  • Lee, C., Gurney, H., Brown, C., Sorio, R., Donadello, N., Tulunay, G., Meier, W., Bacon, M., Maenpaa, J., Petru, E., Gebski, V., Lord, S., Simes, R., et al (2011). Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. British Journal of Cancer, 105(3), 360-365. [More Information]
  • Lee, C., Friedlander, M., Brown, C., Gebski, V., Georgoulopoulos, A., Vergote, I., Pignata, S., Donadello, N., Schmalfeldt, B., Delva, R., Lord, S., Simes, R., et al (2011). Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer. National Cancer Institute. Journal, 103(17), 1338-1342. [More Information]
  • Davis, T., Ting, R., Best, J., Donoghoe, M., Drury, P., Sullivan, D., Jenkins, A., O'Connell, R., Whiting, M., Glasziou, P., Simes, R., Gebski, V., Keech, A., et al (2011). Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia: clinical and experimental diabetes and metabolism, 54(2), 280-290.
  • Brown, A., Gebski, V., Beldham-Collins, R., Hardcastle-Fowler, T., Do, V., Turner, S. (2011). Gold seed fiducial markers for prostate radiation therapy: describing prostate motion. The Radiographer, 58(3), 28-31.
  • Noushi, F., Spillane, A., Uren, R., Gebski, V. (2011). Internal Mammary Lymph Node Metastasis in Breast Cancer: Predictive Models to Assist with Prognostic Influence. The Breast, 20(3), 278-283. [More Information]
  • Lee, C., Simes, R., Brown, C., Lord, S., Wagner, U., Plante, M., Vergote, I., Pisano, C., Parma, G., Burges, A., Gebski, V., et al (2011). Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. British Journal of Cancer, 105(8), 1144-1150. [More Information]
  • Luckett, T., Goldstein, D., Butow, P., Gebski, V., Aldridge, L., McGrane, J., Ng, W., King, M. (2011). Psychological morbidity and quality of life of ethnic minority patients with cancer: a systematic review and meta-analysis. The Lancet Oncology, 12(13), 1240-1248. [More Information]
  • Oh, B., Hu, G., Kao, S., Gebski, V., Walls, R., Truong, L., Beale, P., Clarke, S. (2011). Safety and tolerability of Chinese Herbal Medicine with cancer patients receiving chemotherapy. WebmedCentral, 2(Article ID: WMC001671), 1-11.
  • Clarke, S., Yip, S., Brown, C., van Hazel, G., Ransom, D., Goldstein, D., Jeffrey, G., Tebbutt, N., Buck, M., Lowenthal, R., Boland, A., Gebski, V., Simes, R., et al (2011). Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. European Journal of Cancer, 47(12), 1826-1836. [More Information]
  • Sjoquist, K., Burmeister, B., Smithers, B., Zalcberg, J., Simes, R., Barbour, A., Gebski, V. (2011). Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. The Lancet Oncology, 12(7), 681-692. [More Information]
  • Ellingson, K., Muder, R., Jain, R., Kleinbaum, D., Feng, P., Cunningham, C., Squier, C., Lloyd, J., Edwards, J., Gebski, V., et al (2011). Sustained Reduction in the Clinical Incidence of Methicillin-Resistant Staphylococcus Aureus Colonization or Infection Associated with a Multifaceted Infection Control Intervention. Infection Control and Hospital Epidemiology, 32(1), 1-8. [More Information]
  • Changsirivathanathamrong, D., Wang, Y., Rajbhandari, D., Maghzal, G., Mak, W., Woolfe, C., Duflou, J., Gebski, V., Dos Remedios, C., Celermajer, D., Stocker, R. (2011). Tryptophan metabolism to kynurenine is a potential novel contributor to hypotension in human sepsis. Critical Care Medicine, 39(12), 2678-2683. [More Information]

2010

  • Tebbutt, N., Wilson, K., Gebski, V., Cummins, M., Zannino, D., van Hazel, G., Robinson, B., Broad, A., Ganju, V., Ackland, S., Stockler, M., Simes, R., et al (2010). Capecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study. Journal of Clinical Oncology, 28(19), 3191-3198. [More Information]
  • Grimison, P., Stockler, M., Thomson, D., Olver, I., Harvey, V., Gebski, V., Lewis, C., Levi, J., Boyer, M., Gurney, H., Boland, A., Simes, R., et al (2010). Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial. National Cancer Institute. Journal, 102(16), 1253-1262. [More Information]
  • Davis, T., Ting, R., Best, J., Donoghoe, M., Drury, P., Sullivan, D., Jenkins, A., O'Connell, R., Whiting, M., Glasziou, P., Simes, R., Gebski, V., Keech, A., et al (2010). Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia: clinical and experimental diabetes and metabolism, 54(2), 280-290. [More Information]
  • Goldstein, D., Gainford, M., Brown, C., Tebbutt, N., Ackland, S., van Hazel, G., Jefford, M., Abdi, E., Selva-Nayagam, S., Gebski, V., Miller, D., et al (2010). Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemotherapy and Pharmacology, , 1-7. [More Information]
  • Lee, C., Lord, S., Stockler, M., Coates, A., Gebski, V., Simes, R. (2010). Historical cross-trial comparisons for competing treatments in advanced breast cancer - An empirical analysis of bias. European Journal of Cancer, 46(3), 541-548. [More Information]
  • Noushi, F., Spillane, A., Uren, R., Gebski, V. (2010). Internal mammary node metastasis in breast cancer: Predictive models to determine status & management algorithms. European Journal of Surgical Oncology, 36(1), 16-22. [More Information]
  • Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P., Volgger, B., Vergote, I., Pignata, S., Ferrero, A., Brown, C., et al (2010). Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse. Journal of Clinical Oncology, 28(20), 3323-3329. [More Information]
  • Tarnow-Mordi, W., Gebski, V. (2010). Procalcitonin in intensive care units: the PRORATA trial. The Lancet, 375(9726), 1605. [More Information]
  • Sundaresan, P., Yeghiaian-Alvandi, R., Gebski, V. (2010). Prognostic index to identify patients who may not benefit from whole brain radiotherapy for multiple brain metastases from lung cancer. Journal of Medical Imaging and Radiation Oncology, 54(1), 69-75. [More Information]
  • Janda, M., Gebski, V., Brand, A., Hogg, R., Jobling, T., Land, R., Manolitsas, T., McCartney, A., Nascimento, M., Neesham, D., Pather, S., et al (2010). Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial. Lancet Oncology, 11(8), 772-780.
  • Tebbutt, N., Cummins, M., Sourjina, T., Strickland, A., van Hazel, G., Ganju, V., Gibbs, D., Stockler, M., Gebski, V., Zalcberg, J. (2010). Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. British Journal of Cancer, 102(3), 475-481.
  • Lee, C., Stockler, M., Coates, A., Gebski, V., Lord, S., Simes, R. (2010). Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. British Journal of Cancer, 102(9), 1341-1347. [More Information]
  • Veness, M., Foote, M., Gebski, V., Poulsen, M. (2010). The Role of Radiotherapy Alone in Patients With Merkel Cell Carcinoma: Reporting the Australian Experience of 43 Patients. International Journal of Radiation: Oncology - Biology - Physics, 78(3), 703-709. [More Information]

2009

  • Brown, A., Atyeo, J., Field, N., Cox, J., Bull, C., Gebski, V. (2009). Evaluation of patient preferences towards treatment during extended hours for patients receiving radiation therapy for the treatment of cancer: A time trade-off study. Radiotherapy and Oncology, 90(2), 247-252. [More Information]
  • Green, M., Francis, P., Gebski, V., Harvey, V., Karapetis, C., Chan, A., Snyder, R., Fong, A., Basser, R., Forbes, J. (2009). Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. Annals of Oncology, 20(11), 1813-1817. [More Information]
  • Spillane, A., Noushi, F., Cooper, R., Gebski, V., Uren, R. (2009). High-resolution lymphoscintigraphy is essential for recognition of the significance of internal mammary nodes in breast cancer. Annals of Oncology, 20(6), 977-984. [More Information]
  • Oddone, N., Morgan, G., Palme, C., Perera, L., Shannon, J., Wong, E., Gebski, V., Veness, M. (2009). Metastatic cutaneous squamous cell carcinoma of the head and neck: the Immunosuppression, Treatment, Extranodal spread, and Margin status (ITEM) prognostic score to predict outcome and the need to improve survival. Cancer, 115(9), 1883-1891. [More Information]
  • Tantipalakorn, C., Robertson, G., Marsden, D., Gebski, V., Hacker, N. (2009). Outcome and patterns of recurrence for International Federation of Gynecology and Obstetrics (FIGO) stages I and II squamous cell vulvar cancer. Obstetrics and Gynecology, 113(4), 895-901. [More Information]
  • Gill, G., Wetzig, N., Gebski, V., Stockler, M., Ung, O., Campbell, I., Simes, R. (2009). Sentinel-Lymph-Node-Based Management or Routine Axillary Clearance? One-Year Outcomes of Sentinel Node Biopsy Versus Axillary Clearance (SNAC): A Randomized Controlled Surgical Trial. Annals of Surgical Oncology, 16(2), 266-275. [More Information]
  • Wang, W., Do, V., Hogg, R., Wain, G., Brand, A., Bull, C., Stenlake, A., Gebski, V. (2009). Uterine papillary serous carcinoma: patterns of failure and survival. Australian and New Zealand Journal of Obstetrics and Gynaecology, 49(4), 419-425. [More Information]

2008

  • Obermair, A., Gebski, V., Frumovitz, M., Soliman, P., Schmeler, K., Levenback, C., Ramirez, P. (2008). A phase III randomized clinical trial comparing laparoscopic or robotic radical hysterectomy with abdominal radical hysterectomy in patients with early stage cervical cancer. Journal of Minimally Invasive Gynecology, 15(5), 584-588. [More Information]
  • Nowak, A., Cebon, J., Hargreaves, C., Dhillon, H., Findlay, M., Gebski, V., Stockler, M. (2008). Assessment of health-related quality of life and patient benefit as outcome measures for clinical trials in hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 4, 55-67.
  • Cook, D., Keech, A., Gebski, V., Pike, R., Wonders, S. (2008). Balancing the outcomes: reporting harms (adverse events). In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 132-142). Sydney: AMPCo.
  • Veness, M., Chong, L., Tiver, K., Gebski, V. (2008). Basal cell carcinoma of the nose: An Australian and New Zealand Radiation Oncology patterns-of practice study. Journal of Medical Imaging and Radiation Oncology, 52, 382-393. [More Information]
  • Smith, M., Gill, P., Wetzig, N., Sourjina, T., Gebski, V., Ung, O., Campbell, I., Kollias, J., Coskinas, X., Macphee, A., Simes, R., Stockler, M., et al (2008). Comparing patients' and clinicians' assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial). Breast Cancer Research and Treatment, Online (117)((1)), 1 (99)-11 (109). [More Information]
  • Shakespeare, T., Gebski, V., Tang, J., Lim, K., Lu, J., Zhang, X., Jiang, G. (2008). Influence of the Way Results Are Presented on Research Interpretation and Medical Decision Making: The PRIMER Collaboration Randomized Studies. Medical Decision Making: an international journal, 28(1), 127-137. [More Information]
  • Agustin, C., Grand, M., Gebski, V., Turner, S. (2008). Radiation therapists' perspective on barriers to clinical trials research. Journal of Medical Imaging and Radiation Oncology, 52(2), 178-182. [More Information]

2007

  • Brunnberg, L., Smith, J., Hannon, R., Gebski, V., Cullis-Hill, D. (2007). A comparator study of pentosan polysulfate and carprofen on the clinical signs of pain and lameness in osteoarthritis [Eine Vergleichsstudie über Pentosanpolysulfat und Carprofen über die Klinischen Syptome Schmerz und Lahmheit bei Osteoarthritis]. Kleintier-Praxis, 52(3), 133-142.
  • Findlay, M., Storey, D., Gebski, V., Hargreaves, C., Cullingford, G., Boyer, M., Trotter, J., Archer, S., Davidson, A., Johnston, P., Yuen, J., Dhillon, H., et al (2007). A pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer: Australasian Gastrointestinal Trials Group study 9601. ANZ Journal of Surgery, 77(4), 247-252.
  • Keech, A., Gebski, V., Forder, P. (2007). Allocation concealment and blinding: when ignorance is bliss. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 54-64). Sydney: AMPCo.
  • Gebski, V., Keech, A., Simes, R. (2007). Applying subgroup analysis to individual patient decisions. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 114-122). Sydney: AMPCo.
  • Keech, A., Gebski, V., Burgess, D. (2007). Baseline data in clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 86-91). Sydney: AMPCo.
  • Shakespeare, T., Lu, J., Tang, J., Lim, K., Mukherjee, R., Back, M., Gebski, V. (2007). Choosing my treatment: incorporating informational and decision-making needs into a Preference Compass. RANZCR, 58th Annual Scientific Meeting.
  • Keech, A., Gebski, V., Kirby, A. (2007). Determining the sample size in a clinical trial. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 28-38). Sydney: AMPCo.
  • Nordsmark, M., Eriksen, J., Gebski, V., Alsner, J., Horsman, M., Overgaard, J. (2007). Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiotherapy and Oncology, 83(3), 389-397.
  • Tai, B., De Stavola, B., de Gruttola, V., Gebski, V., Machin, D. (2007). First-event or marginal estimation of cause-specific hazards for analysing correlated multivariate failure-time data? Statistics in Medicine, Published online 5 June 2007(28), 922-936. [More Information]
  • Keech, A., Gebski, V., Vachan, B. (2007). Flow of participants in randomised studies. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 72-78). Sydney: AMPCo.
  • Keech, A., Seale, J., Gebski, V. (2007). Generalising the results of trials to clinical practice. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 149-153). Sydney: AMPCo.
  • Keech, A., Gebski, V., Heritier, S. (2007). Inclusion of patients in clinical trial analysis: the intention-to-treat principle. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 92-98). Sydney: AMPCo.
  • Keech, A., Gebski, V., Pike, R. (2007). Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials. Sydney: AMPCo.
  • Keech, A., Pike, R., Granger, R., Gebski, V. (2007). Interpreting the results of a clinical trial. Medical Journal of Australia, 186(9), 318-319. [More Information]
  • Keech, A., Gebski, V., Pike, R., Granger, R. (2007). Interpreting the results of a clinical trial. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 143-148). Sydney: AMPCo.
  • Keech, A., Ghersi, D., Gebski, V., Pike, R. (2007). Introducing the report of a randomised controlled trial: the title, abstract, scientific background and rationale. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 8-10). Sydney: AMPCo.
  • Lin, C., Turner, S., Mai, T., Kneebone, A., Gebski, V. (2007). Late rectal and urinary toxicity from conformal, dose-escalated radiation therapy for prostate cancer: A prospective study of 402 patients. Journal of Medical Imaging and Radiation Oncology, 51(6), 578-583. [More Information]
  • O'Connell, R., Gebski, V., Keech, A. (2007). Making sense of trial results: outcomes and estimation. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 99-104). Sydney: AMPCo.
  • Keech, A., Gebski, V. (2007). Managing the resource demand of a large sample in clinical trials: can you succeed with fewer subjects? In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 39-45). Sydney: AMPCo.
  • Keech, A., Gebski, V., Lord, S. (2007). Multiple analyses in clinical trials: sound science or data dredging? In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 123-131). Sydney: AMPCo.
  • Ahern, V., Koh, E., Gebski, V., Sathiyaseelan, Y. (2007). Paediatric medulloblastoma: Patterns of care and radiotherapy quality assurance in Australia. Journal of Medical Imaging and Radiation Oncology, 51(5), 458-464. [More Information]
  • Tinker, A., Gebski, V., Fitzharris, B., Buck, M., Stuart-Harris, R., Beale, P., Goldrick, A., Rischin, D. (2007). Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel-ANZGOG 02-01. Gynecologic Oncology, 104(3), 647-653. [More Information]
  • Wilcken, N., Gebski, V., Pike, R., Keech, A. (2007). Putting results of a clinical trial into perspective. Medical Journal of Australia, 186(7), 368-370. [More Information]
  • Wilcken, N., Gebski, V., Pike, R., Keech, A. (2007). Putting results of a clinical trial into perspective. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 154-161). Sydney: AMPCo.
  • Beller, E., Gebski, V., Keech, A. (2007). Randomisation in clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 46-53). Sydney: AMPCo.
  • Gebski, V., Beller, E., Keech, A., Van Der Weyden, M. (2007). Randomised Controlled Trials: Elements of a Good Study. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 7-22). Sydney: AMPCo.
  • Keech, A., Gebski, V., Beller, E., Van Der Weyden, M. (2007). Randomised controlled trials: elements of a good study. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 1-7). Sydney: AMPCo.
  • Hague, W., Keech, A., Gebski, V., Pike, R. (2007). Recruitment to randomised studies. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 78-85). Sydney: AMPCo.
  • Keech, A., Gebski, V. (2007). Selecting participants for clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 11-15). Sydney: AMPCo.
  • Ahern, V., Boyages, J., Gebski, V., Moon, D., Wilcken, N. (2007). Selective Mastectomy in the Management of Locally Advanced Breast Cancer. International Journal of Radiation: Oncology - Biology - Physics, 68. [More Information]
  • Brighton, J., Gebski, V., Keech, A. (2007). Specifying intervention in a clinical trial. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 16-20). Sydney: AMPCo.
  • Keech, A., Gebski, V., Marschner, C. (2007). Specifying objectives and outcomes for clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 21-26). Sydney: AMPCo.
  • Keech, A., Gebski, V. (2007). Statistical methods in clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 65-71). Sydney: AMPCo.
  • Gebski, V., Byth Wilson, K., Langlands, A. (2007). Statistical rigour is essential to clinical prediction. ANZ Journal of Surgery, 77(7), 597-598. [More Information]
  • Cook, D., Keech, A., Gebski, V. (2007). Subgroup analysis in clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 105-113). Sydney: AMPCo.
  • Gebski, V., Burmeister, B., Smithers, B., Foo, K., Zalcberg, J., Simes, R. (2007). Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncology, 8(3), 226-234. [More Information]
  • Matsuura, Y., Robertson, G., Marsden, D., Soo-Nyung, K., Gebski, V., Hacker, N. (2007). Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecologic Oncology, 104(2), 406-410. [More Information]
  • Walleser, S., Griffiths, A., Lord, S., Howard, K., Solomon, M., Gebski, V. (2007). What is the value of computered tomography colonography in patients screening positive for fecal occult blood? A systematic review and economic evaluation. Clinical Gastroenterology and Hepatology, 5(12), 1439-1446. [More Information]
  • Wilcken, N., Gebski, V., Keech, A., Pike, R. (2007). Words, Words, Words. Medical Journal of Australia, 187(4), 256-256.

2006

  • Stockler, M., Sourjina, T., Harvey, V., Frances, P., Byrne, M., van Hazel, G., Fitzharris, B., Ackland, S., Finch, K., Lindsay, D., Gebski, V., Simes, R., Coates, A., et al (2006). A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment. Breast Cancer Research and Treatment, 100(Supplement 1), S278-S278.
  • Nordsmark, M., Gebski, V. (2006). Assays directed to assess tumor hypoxiain human tumor and their implications as prognostic and predictive assays. ICTR 3rd International Conference on Translational Research.
  • Shakespeare, T., Gebski, V., Thiagarajan, A., Lu, J. (2006). Development of a spreadsheet for the calculation of new tools to improve the reporting of the results of medical research. Medical Informatics and the Internet in Medicine, 31(2), 121-127. [More Information]
  • Jones, M., Onslow, M., Packman, A., Gebski, V. (2006). Guidelines for statistical analysis of percentage of syllables stuttered data. Journal of Speech, Language, and Hearing Research, 49(4), 867-878. [More Information]
  • Gill, P., Gebski, V., Wetzig, N., Ung, O., Campbell, I., Collins, J., Sourjina, T., Coskinas, X., Stockler, M., Simes, R. (2006). Sentinel node (SN) based management causes less arm swelling and better quality of life than routine axillary clearance (AC): 1 year outcomes of the SNAC trial. Breast Cancer Research and Treatment, 100(Supplement 1), S14-S14.
  • Cebon, J., Hargreaves, C., Stockler, M., Boyer, M., Nowak, A., Dhillon, H., Gebski, V., Dickman, B., Findlay, M., Poon, A., et al (2006). Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. British Journal of Cancer, 95(7), 853-861. [More Information]
  • Gebski, V., Lagleva, M., Keech, A., Simes, R., Langlands, A. (2006). Survival Effects of Postmastectomy Adjuvant Radiation Therapy Using Biologically Equivalent Doses: A Clinical Perspective - [Response]. National Cancer Institute. Journal, 98(17), 1021-1022.
  • Gebski, V., Lagleva, M., Keech, A., Simes, R., Langlands, A. (2006). Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective. National Cancer Institute. Journal, 98(1), 26-38. [More Information]
  • Dwyer, M., Gebski, V., Jayamohan, J. (2006). The bottom line: outcomes after conservation treatment in anal cancer. Journal of Medical Imaging and Radiation Oncology, 50(1), 46-51. [More Information]
  • Nordsmark, M., Gebski, V., Loncaster, J., Aquino-Parsons, C., Chou, S., West, C., Lindegaard, J., Havsteen, H., Davidson, S., Raleigh, J., Overgaard, J. (2006). The Prognostic Value of Pimonidazole and Tumor pO2 in Human Cervix Carcinomas after Radiation Therapy: An International Multi-Centre Study. ICTR 3rd International Conference on Translational Research.
  • Nordsmark, M., Loncaster, J., Aquino-Parsons, C., Chou, S., Gebski, V., West, C., Lindegaard, J., Havsteen, H., Davidson, S., Hunter, R., et al (2006). The prognostic value of pimonidazole and tumour pO(2) in human cervix carcinomas after radiation therapy: A prospective international multi-center study. Radiotherapy and Oncology, 80(2), 123-131. [More Information]
  • Matsuura, Y., Robertson, G., Marsden, D., Kim, S., Gebski, V., Hacker, N. (2006). Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecologic Oncology, 104(2), 406-410. [More Information]
  • Janda, M., Gebski, V., Forder, P., Jackson, D., Williams, G., Obermair, A. (2006). Total laparoscopic versus open surgery for stage 1 endometrial cancer: The LACE randomized controlled trial. Contemporary Clinical Trials, 27(4), 353-363. [More Information]
  • Veness, M., Foroudi, F., Gebski, V., Timms, I., Sathiyaseelan, Y., Vachan, B., Tiver, K. (2006). Use of topical misoprostol to reduce radiation-induced mucositis: Results of a randomized, double-blind, placebo-controlled trial. Journal of Medical Imaging and Radiation Oncology, 50(5), 468-474. [More Information]

2005

  • Veness, M., Gebski, V., Morgan, G. (2005). Adjuvant locoregional radiotherapy as best practice in patients with Merkel cell carcinoma of the head and neck. Head and Neck, 27(3), 208-216. [More Information]
  • Gebski, V., Lagleva, M., Simes, R., Keech, A., Langlands, A. (2005). Adjuvant Radiotherapy in Early Breast Cancer: The Clinical Utility of Published Meta-Analysis. RANZCR, 55th Annual Scientific Meeting.
  • Forder, P., Gebski, V., Keech, A. (2005). Allocation concealment and blinding [reply]. Medical Journal of Australia, 183(3), 165-166.
  • Forder, P., Gebski, V., Keech, A. (2005). Allocation concealment and blinding: when ignorance is bliss. Medical Journal of Australia, 182(2), 87-89. [More Information]
  • Veness, M., Morgan, G., Gebski, V., Sathiyaseelan, Y. (2005). Anterior tongue cancer and the incidence of cervical lymph node metastases with increasing tumour thickness: should elective treatment to the neck be standard practice in all patients? ANZ Journal of Surgery, 75(3), 101-105. [More Information]
  • Gebski, V. (2005). Calendar and Event Based Clinical Trial Designs and Surrogate Outcomes. Cardiac Society of Australia and New Zealand.
  • Gebski, V., Heritier, S., Pillai, A., Luke, V., Simes, R., Keech, A. (2005). Computer modelling of adaptive randomisation schemes in large scale randomised controlled trials. 20th International Workshop on Statistical Modelling, Sydney, Australia: University of Western Sydney.
  • Heritier, S., Gebski, V., Pillai, A. (2005). Dynamic balancing randomization in controlled clinical trials. Statistics in Medicine, 24(24), 3729-3741. [More Information]
  • Shakespeare, T., Thiagarajan, A., Gebski, V. (2005). Evaluation of the quality of radiotherapy randomized trials for painful bone metastases. Cancer, 103(9), 1976-1981. [More Information]
  • Veness, M., Perera, L., McCourt, J., Shannon, J., Hughes, T., Morgan, G., Gebski, V. (2005). Merkel cell carcinoma: improved outcome with adjuvant radiotherapy. ANZ Journal of Surgery, 75(5), 275-281. [More Information]
  • Foo, K., Gebski, V., Yeghiaian-Alvandi, R., Foroudi, F., Vachan, B. (2005). Outcome following radiotherapy for loco-regionally recurrent non-small cell lung cancer. Journal of Medical Imaging and Radiation Oncology, 49(2), 108-112. [More Information]
  • Wetzig, N., Gill, P., Ung, O., Collins, J., Kollias, J., Gillett, D., Gebski, V., Greig, C., Ray, A., Stockler, M. (2005). Participation in the RACS sentinel node biopsy versus axillary clearance trial. ANZ Journal of Surgery, 75(3), 98-100. [More Information]
  • Lataifeh, I., Marsden, D., Robertson, G., Gebski, V., Hacker, N. (2005). Presenting symptoms of epithelial ovarian cancer. Australian and New Zealand Journal of Obstetrics and Gynaecology, 45(3), 211-4. [More Information]
  • Jones, M., Onslow, M., Packman, A., Williams, S., Ormond, T., Schwarz, I., Gebski, V. (2005). Randomised controlled trial of the Lidcombe programme of early stuttering intervention. BMJ: British Medical Journal, 331(7518), 659-661. [More Information]
  • Burmeister, B., Smithers, B., Gebski, V., Fitzgerald, L., Simes, R., Devitt, P., Ackland, S., Gotley, D., Joseph, D., Millar, J., Walpole, E., et al (2005). Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology, 6(9), 659-668. [More Information]
  • Veness, M., Morgan, G., Palme, C., Gebski, V. (2005). Surgery and Adjuvant Radiotherapy in Patients with Cutaneous Head and Neck Squamous Cell Carcinoma Metastatic to Lymph Nodes: Combined Treatment Should be Considered Best Practice. The Laryngoscope, 115(5), 870-875. [More Information]
  • Qian, M., Wang, D., Watkins, W., Gebski, V., Yan, Y., Li, M., Chen, Z. (2005). The effects of iodine on intelligence in children: a meta-analysis of studies conducted in China. Asia Pacific Journal of Clinical Nutrition, 14(1), 32-42. [More Information]
  • Gebski, V. (2005). The Results from a Meta-Analysis of Preoperative Therapy for Oesophageal cancer. Clinical Oncology Society of Australia.

2004

  • Keech, A., Wonders, S., Cook, D., Gebski, V. (2004). Balancing the outcomes: reporting adverse events. Medical Journal of Australia, 181(4), 215-218.
  • Gebski, V. (2004). Book Review: Statistics in Clinical Oncology. Statistics in Medicine, 23(13), 2151-2153.
  • Chin, Y., Jayamohan, J., Clouston, P., Gebski, V., Vachan, B. (2004). Driving and Patients with Brain Tumours: a postal survey of Neurosurgeons, Neurologists and Radiation Oncologists. Journal of Clinical Neuroscience, 11(5), 471-474. [More Information]
  • Byth Wilson, K., Gebski, V. (2004). Factorial designs: a graphical aid for choosing study designs accounting for interaction. Clinical Trials, 1(3), 315-325.
  • Gebski, V., Vachan, B. (2004). Flexetrials an Introduction to Inform. Taiwan-Australian International Symposium on Clinical Trials.
  • Seale, J., Gebski, V., Keech, A. (2004). Generalising the results of trials to clinical practice. Medical Journal of Australia, 181(10), 558-560.
  • O'Connell, R., Gebski, V., Keech, A. (2004). Making Sense Of Trial Results: Outcomes And Estimation. Medical Journal of Australia, 180(3), 128-130.
  • Gebski, V., Vachan, B. (2004). Management of Oncology Trials and Co-operative Groups in Australia. Taiwan-Australian International Symposium on Clinical Trials.
  • Lord, S., Gebski, V., Keech, A. (2004). Multiple Analyses In Clinical Trials: Sound Science Or Data Dredging? Medical Journal of Australia, 181(8), 452-454.
  • Tarnow-Mordi, W., Gebski, V., Cust, A. (2004). Noninvasive Ventilation: To the Editor. New England Journal of Medicine, 351(12), 1257-1257. [More Information]
  • Cook, D., Gebski, V., Keech, A. (2004). Subgroup analysis in clinical trials. Medical Journal of Australia, 180(6), 289-291.
  • Simes, R., Gebski, V., Keech, A. (2004). Subgroup analysis: application to individual patient decisions. Medical Journal of Australia, 180(9), 467-469. [More Information]

2003

  • Smithers, B., Burmeister, B., Fitzgerald, L., Gebski, V., Denham, J., Devitt, P., Ackland, S., Joseph, D., Millar, J., North, J., Walpole, E., et al (2003). A randomised controlled trial of surgery alone compared with chemoradiation and surgery: a focus on surgical outcomes. 56th Annual Cancer Symposium of the Society of Surgical Oncology.
  • Kneebone, A., Gebski, V., Hogendoorn, N., Turner, S. (2003). A randomised trial evaluating rigid immobilization for pelvic irradiation. International Journal of Radiation: Oncology - Biology - Physics, 56(4), 1105-1111.
  • Veness, M., Morgan, G., Sathiyaseelan, Y., Gebski, V. (2003). Anterior tongue cancer: age is not a predictor of outcome and should not alter treatment. ANZ Journal of Surgery, 73(11), 899-904.
  • Kneebone, A., Turner, S., Berry, M., Vachan, B., Gebski, V. (2003). Australian prostate-specific antigen outcome and toxicity following radiation therapy for localized prostate cancer. Journal of Medical Imaging and Radiation Oncology, 47(4), 422-427.
  • Burgess, D., Gebski, V., Keech, A. (2003). Baseline data in clinical trials. Medical Journal of Australia, 11, 105-107.
  • Gebski, V. (2003). Clinical Trials and Tribulations. 43rd Annual Scientific Meeting International Dental Research Association Conference.
  • Kirby, A., Gebski, V., Keech, A. (2003). Determining the sample size in a clinical trial [in reply]. Medical Journal of Australia, 178(7), 358-358.
  • Vachan, B., Gebski, V., Keech, A. (2003). Flow of participants in randomised studies. Medical Journal of Australia, 178, 347-349.
  • Heritier, S., Gebski, V., Keech, A. (2003). Inclusion of patients in clinical trial analysis: the intention-to-treat principle. Medical Journal of Australia, 11, 438-440.
  • Keech, A., Gebski, V. (2003). Managing the resource demands of a large sample size in clinical trials: can you succeed with fewer subjects. Medical Journal of Australia, 178(7), 356-357.
  • Hornbuckle, J., Culjak, G., Jarvis, E., Gebski, V., Coates, A., Mann, G., Kefford, R. (2003). Patterns of metastases in familial and non-familial melanoma. Melanoma Research: a journal for basic, translational and clinical research in melanoma, 13(1), 105-109.
  • Burmeister, B., Smithers, B., Gebski, V., Fitzgerald, L., Devitt, P., Ackland, S., Joseph, D., Denham, J. (2003). Preoperative chemoradiation therapy for oesophageal cancer-results of the Australasian Study IG9401. 12th International Conference on Radiation Research (ICRR).
  • Hague, W., Gebski, V., Keech, A. (2003). Recruitment to randomised studies. Medical Journal of Australia, 178(11), 579-581.
  • Babington, S., Veness, M., Vachan, B., Gebski, V., Morgan, G. (2003). Squamous cell carcinoma of the lip: is there a role for adjuvant radiotherapy in improving local control following incomplete or inedequate excision? ANZ Journal of Surgery, 73(8), 621-625.
  • Gebski, V., Keech, A. (2003). Statistical methods in clinical trials. Medical Journal of Australia, 11, 182-184.
  • Hyam, D., Conway, R., Sathiyaseelan, Y., Gebski, V., Morgan, G., Walker, D., Veness, M. (2003). Tongue cancer: do patients younger than 40 do worse? Australian Dental Journal, 48(1), 50-54.
  • Barton, M., Jacob, S., Gebski, V. (2003). Utility-adjusted analysis of the cost of palliative radiotherapy for bone metastases. Journal of Medical Imaging and Radiation Oncology, 47(3), 274-278.

2002

  • Smith, J., Shannon, R., Brunnberg, L., Gebski, V., Cullis-Hill, D. (2002). A multicentre clinical study of the efficacy of sodium pentosan polysulfate and carprofen in canine osteoarthritis (osteoarthrosis). Norsk Veterinaertidsskrift, , 123-130.
  • Cullingford, G., Findlay, M., Storey, D., Boyer, M., Trotter, J., Archer, S., Davidson, A., Johnston, P., Gebski, V., Dhillon, H. (2002). A phase II feasibility study of pre-operative and post-operative chemotherapy (epirubicin, cisplatin and 4FU (ECF)) in patients with advanced but operable gastric cancer: and Australasian Gastro-Intestinal Trials Group (AGITG) study (AG9601). 38th Annual Meeting of ASCO.
  • Burmeister, B., Smithers, B., Fitzgerald, L., Gebski, V., Devitt, P., Ackland, S., Joseph, M., Millar, J., Millar, J., Walpole, E., et al (2002). A randomized phase III trial of preoperative chemoradiation followed by surgery versus surgery alone for localized resectable cancer of the esophagus. 38th Annual Meeting of ASCO.
  • Lewis, J., Beldham-Collins, R., Gebski, V. (2002). Changes in stress perceptions of radiation therapists following a debriefing program. The Radiographer, 49(3), 133-135.
  • Langlands, A., Gebski, V., Hirsch, D., Tattersall, M. (2002). Delay in the clinical diagnosis of breast cancer: estimating its effect on prognosis, with particular reference to medical litigation. The Breast, 11(5), 386-393.
  • Kirby, A., Gebski, V., Keech, A. (2002). Determining the sample size in a clinical trial. Medical Journal of Australia, , 256-257.
  • Finnie, J., Blumbergs, P., Manavis, J., Utteridge, T., Gebski, V., Davies, R., Vernon-Roberts, B., Kuchel, T. (2002). Effect of long-term mobile communication microwave exposure on vascular permeability in mouse brain. Pathology, 34(4), 344-347.
  • Wetzig, N., Gill, P., Ung, O., Collins, J., Kollias, J., Gillette, D., Gebski, V., Greig, C., Ray, A., Stockler, M. (2002). Eligibility and Choice in the royal Australiasian College of Surgeons "SNAC Trial" of Sentinel Node Biopsy versus axillary clearance in operable breast cancer. 3rd International Sentinel Node Congress.
  • Shakespeare, T., Dwyer, M., Mukherjee, R., Yeghiaian-Alvandi, R., Gebski, V. (2002). Estimating risks of radiotherapy complications as part of informed consent: the high degree of variability between radiation oncologists may be related to experience. International Journal of Radiation: Oncology - Biology - Physics, 54(3), 647-653.
  • Cuzick, J., Forbes, J., Edwards, R., Baum, M., Cawthorn, S., Coates, A., Hamed, H., Howell, A., Powels, T., Dhillon, H., Gebski, V., Simes, R. (2002). First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial. The Lancet, 360(9336), 817-824.
  • Cuzjik, J., Dhillon, H., Gebski, V., Simes, R. (2002). First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. The Lancet, 360(9336), 817-824.
  • Utteridge, T., Gebski, V., Finnie, J., Vernon-Roberts, B., Kuchel, T. (2002). Long-term exposure of Eu-Pim 1 transgenic mice to 898.4 MHz microwaves does not increase lymphoma incidence. Radiation Research, 158(3), 357-364.
  • Keech, A., Gebski, V. (2002). Managing the resource demands of a large sample size in clinical trials: can you succeed with fewer subjects? Medical Journal of Australia, 177(8), 437-439.
  • Tai, B., White, I., Gebski, V., Machin, D. (2002). On the issue of 'multiple' first failures in competing risks analysis. Statistics in Medicine, 21(15), 2243-2255. [More Information]
  • Veness, M., Chua, M., Morgan, G., Shakespeare, T., Hehir, A., Gebski, V., Vachan, B., Tiver, K. (2002). Parotid lymph-node metastases from cutaneous squamous-cell carcinomas: Treatment outcome and prognostic factors following surgery and adjuvant radiotherapy. Journal of Medical Imaging and Radiation Oncology, 46(2), 174-179.
  • Liu, P., Gebski, V., Turner, L., Conway, A., Wishart, S., Handelsman, D. (2002). Predicting pregnancy and spermatogenesis by survival analysis during gonadotrophin treatment of gonadotrophin-deficient infertile men. Human Reproduction, 17(3), 625-633.
  • Foroudi, F., Bull, C., Gebski, V. (2002). Radiation Therapy for Cervix Carcinoma: Benefits of Individualized Dosimetry. Clinical Oncology, 14(1), 43-49.
  • Beller, E., Gebski, V., Keech, A. (2002). Randomisation in clinical trials. Medical Journal of Australia, 177(10), 565-567.
  • Gray, B., Van Hazel, G., Anderson, J., Price, A., Moroz, P., Bower, G., Blackwell, A., Gebski, V. (2002). Randomised phase II trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone on advanced colorectal hepatic metastases. 38th Annual Meeting of ASCO.
  • Tay, E., Grant, P., Gebski, V., Hacker, N. (2002). Secondary Cytoreduction Surgery for Recurrent Epithelial Ovarian Cancer. Obstetrics and Gynecology, 100(6), 1359-1360.
  • Tay, E., Grant, P., Gebski, V., Hacker, N. (2002). Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstetrics and Gynecology, 99(6), 1008-1013.
  • Langlands, A., Gebski, V. (2002). Sharp v Port Kembla RSL club: establishing causation of laryngeal cancer by environmental tobacco smoke. Medical Journal of Australia, 176(9), 448-448.
  • Brighton, J., Gebski, V., Keech, A. (2002). Specifying interventions in a clinical trial. Medical Journal of Australia, , 281-282.
  • Gebski, V., Marschner, C., Keech, A. (2002). Specifying objectives and outcomes for clinical trials. Medical Journal of Australia, 176(10), 491-492.
  • Jones, M., Gebski, V., Onslow, M., Packman, A. (2002). Statistical power in stuttering research: a tutorial. Journal of Speech, Language, and Hearing Research, 45(2), 243-255.
  • Gebski, V., Simes, R. (2002). Survival plots for interpreting trial results. International Clinical Trials Symposium.
  • Hu, G., Walls, R., Bass, D., Bullock, R., Grayson, D., Jones, M., Gebski, V. (2002). The Chinese herbal formulation Biminne in management of perennial allergic rhinitis: a randomized, double-blind, placebo-controlled, 12-week clinical trial. Annals of Allergy, Asthma, and Immunology, 88(5), 478-487.
  • Grogan, M., Rangan, A., Gebski, V., Boyages, J. (2002). The value of follow-up of patients with early breast cancer treated with conservative surgery and radiation therapy. The Breast, 11(2), 163-169.

2001

  • Smith, J., Hannon, R., Brunnberg, L., Gebski, V., Cullis-Hill, D. (2001). A randomised, double-blind, comparator clinical study of the efficacy of sodium pentosan polysulfate injection and carprofen capsules in arthritic dogs. Osteoarthritis and Cartilage, 9(Supplement 2), S21-S22.
  • Delaney, G., Gebski, V., Jalaludin, B., Griffiths, B. (2001). Basic treatment equivalent (BTE) – a better measure of linear accelerator workload. ECCO 11. European Cancer Conference.
  • Lumley, T., Simes, R., Gebski, V., Hudson, H. (2001). Combining components of quality of life to increase precision and evaluate trade-offs. Statistics in Medicine, 20(21), 3231-3249.
  • Lumley, T., Simes, R., Gebski, V., Hudson, M. (2001). Combining components of quality of life to increase precision and evaluate trade-offs. Statistics in Medicine, 20, 3231-3249.
  • Toner, G., Stockler, M., Boyer, M., Jones, M., Thomson, D., Harvey, V., Olver, I., Dhillon, H., McMullen, A., Gebski, V., Levi, J., Simes, R. (2001). Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. The Lancet, 357(9528), 739-745.
  • Gebski, V., Tai, B., Machin, D., White, I. (2001). Competing risks analysis of patients with osteosarcoma: a comparison of four different approaches. Statistics in Medicine, 20, 661-684.
  • Tai, B., Machin, D., White, I., Gebski, V. (2001). Competing risks analysis of patients with osteosarcoma: a comparison of four different approaches. Statistics in Medicine, 20(5), 661-684.
  • Hui, A., Barton, B., Gebski, V. (2001). Complications of Radiotherapy for Rectal Cancer A Systematic Review. Royal Australian & New Zealand College of Radiologists, 52nd Annual Scientific Meeting.
  • Jones, M., Gebski, V., Onslow, M., Packman, A. (2001). Design of randomized controlled trials principles and methods applied to a treatment for early stuttering. Journal of Fluency Disorders, 26, 247-267.
  • Jones, M., Gebski, V., Onslow, M., Packman, A. (2001). Design of randomized controlled trials: Principles and methods applied to a treatment for early stuttering. Journal of Fluency Disorders, 26(4), 247-267.
  • Chin, Y., Jayamohan, J., Gebski, V. (2001). Driving and Patients with Brain Tumours: A Postal Survey of Neurosurgeons, Neurologists and Radiation Oncologists in New South Wales. Royal Australian & New Zealand College of Radiologists, 52nd Annual Scientific Meeting.
  • Gebski, V., Finnie, J., Blumbergs, P., Manavis, J., Utteridge, T., Swift, J., Vernon-Roberts, B., Kuchel,, T. (2001). Effect of global system for mobile communication (gsm)-like radiofrequency fields on vascular permeability in mouse brain. Pathology, 33, 338-340.
  • Finnie, J., Blumbergs, P., Manavis, J., Utteridge, T., Gebski, V., Swift, J., Vernon-Roberts, B., Kuchel, T. (2001). Effect of Global System for Mobile Communication (GSM)-Like Radiofrequency Fields on Vascular Permeability in Mouse Brain. Pathology, 33(3), 338-340.
  • Gebski, V., Finnie, J., Van, D., Manavis, J., Summersides, G., Blumbergs, P. (2001). Effect of impact on different regions of the head of lambs. Journal of Comparative Pathology, 124, 159-164.
  • Finnie, J., Van Den Heuvel, C., Gebski, V., Manavis, J., Summersides, G., Blumbergs, P. (2001). Effect of Impact on Different Regions of the Head of Lambs. Journal of Comparative Pathology, 124(2-3), 159-164.
  • Gebski, V., Veness, M., Simes, R., Shakespeare, T. (2001). Improving interpretation of clinical studies by use of confidence intervals, clinical significnce cureves, and risk analysis. The Lancet, 357, 1349-1353.
  • Shakespeare, T., Gebski, V., Veness, M., Simes, R. (2001). Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk-benefit contours. The Lancet, 357(9265), 1349-1353.
  • Turner, S., Gruenewald, S., Spry, N., Gebski, V. (2001). Less pain does equal better quality following stronutium-89 therapy for mestatic prostate cancer. British Journal of Cancer, 84 (3), 297-302.
  • Turner, S., Gruenewald, S., Spry, N., Gebski, V. (2001). Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. British Journal of Cancer, 84(3), 297-302.
  • Koh, E., Ahern, V., Sathiyaseelan, Y., Gebski, V. (2001). Radiotherapy Quality Assurance for Paediatric Medulloblastoma in Australia. Royal Australian & New Zealand College of Radiologists, 52nd Annual Scientific Meeting.
  • Gray, B., Van Hazel, G., Hope,, M., Burton, M., Moroz, P., Anderson, J., Gebski, V. (2001). Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Annals of Oncology, 12(12), 1711-1720.
  • Gebski, V., Gray, B., Van, H., Hope,, M., Burton, M., Moroz, P., Anderson, J. (2001). Randomised trial of SIR-spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastses from primary large bowel cancer. Annals of Oncology, 12, 1711-1720.
  • Gebski, V., Beller, E., Keech, A. (2001). Randomized controlled trails: elements of a good study. Medical Journal of Australia, 175, 272-274.
  • Ghersi, D., Gebski, V., Keech, A. (2001). Scientific background and rationale for a randomised controlled trial. Medical Journal of Australia, 175(7), 386-386.
  • Keech, A., Gebski, V. (2001). Selecting participants for clinical trials. Medical Journal of Australia, 175(9), 490-491.
  • Dwyer, M., Gebski, V., Jayamohan, J. (2001). The Bottom Line: Outcomes following Conservation Therapy in Anal Cancer. Clinical Oncological Society of Australia.
  • Thompson, S., Turner, S., Gebski, V. (2001). The IPSS: A Better Way of Measuring Urinary Morbidity from Prostate Brachytherapy? Royal Australian & New Zealand College of Radiologists, 52nd Annual Scientific Meeting.
  • Dealney, G., Gebski, V., Langlands, A. (2001). To BTE or Not BTE: That is the Question. Clinical Oncology, 13(4), 311-312.
  • Shakespeare, T., Dwyer, M., Mukherjee, R., Yeghiaian-Alvandi, R., Gebski, V. (2001). Variability in estimating late normal tissue toxicity for patients receiving radiotherapy. Does experience influence whet we are telling our patients. ECCO 11. European Cancer Conference.

To update your profile click here. For support on your academic profile contact .